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Abstract 
Radiation therapy of the prostate relies on maximising radiation dose delivery to the 
tumour to ensure optimal outcomes.  Escalation of treatment doses has been shown 
to improve tumour control.  Unpredictable prostate motion, however, limits the 
ability to target the tumour without increasing toxicity.  Therefore, strategies are 
required to account for the uncertainty in prostate position, such as image-guided 
radiation therapy (IGRT).  The purpose of this thesis was to compare two of the most 
commonly available methods of prostate IGRT: implanted fiducial markers (FMs) 
and cone beam computed tomography (CBCT).   
 
Intraprostatic FMs have become the standard for prostate localisation in recent years.  
Small markers, implanted in the prostate, are used to correct for displacements at the 
time of treatment, using radiographic imaging.  While an efficient means of prostate 
IGRT, FMs have associated complicating factors, such as the risk of infection.  The 
financial implications, from supply and implantation, can be prohibitive.  Some 
patients are unable to undergo the surgical procedure and therefore cannot benefit 
from FM-based IGRT. An accurate IGRT solution, independent of FMs, is therefore 
highly desirable. Recently, CBCT imaging technology has been integrated into many 
radiation treatment units.  Soft-tissue imaging with CBCT potentially provides the 
opportunity to localise the prostate without the use of FMs.   
 
This thesis explores the use of IGRT strategies for radiation therapy of the prostate, 
comparing the use of FMs and soft-tissue localisation.  This investigation was 
performed in two parts.  Daily kilovoltage (kV) planar imaging with localisation to 
FMs was performed for six patients in both the online and offline setting for a total 
of 225 fractions.  The assessment of volumetric imaging included localisation of 
FMs and soft-tissue prostate using 185 CBCT images for another six patients.  
Registration of the planar and volumetric images was individually performed by 
three radiation therapists (RTs) in the offline environment. 
 
Interobserver agreement from each IGRT method was assessed by comparing the 
localisation for each observer for each of the IGRT methods: FMs on planar kV 
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imaging, FMs on CBCT, and soft-tissue on CBCT.  Bland-Altman limits of 
agreement (LoA) analysis were performed to compare the localisation from FMs and 
soft-tissue on CBCT. 
 
The assessment of planar kV images found interobserver agreement was within 
clinically acceptable 95 % limits of agreement (± 2.0 mm).  For the CBCT images, a 
modified Bland-Altman analysis of interobserver agreement resulted in clinically 
acceptable differences: within ± 2.0 mm for FMs and within ± 3.0 mm for soft-tissue 
localisation.  Soft-tissue alignment was found to have greater interobserver 
variability than alignment to FMs, 
 
The comparison of localisation based on FMs or soft-tissue using CBCT resulted in 
95 % LoA of -4.9 to 2.6 mm, -1.6 to 2.5 mm, and -4.7 to 1.9 mm in the superior-
inferior, left-right and anterior-posterior planes respectively. 
 
RTs were able to make consistent and reliable judgements when matching FMs on 
planar kV imaging or CBCT.  The relatively large interobserver variability found for 
soft-tissue alignment demonstrates that intraprostatic FMs are able to improve 
consistency of   prostate localisation.  Significant differences were found between 
soft-tissue alignment and the predicted FM position.  The decreased consistency of 
CBCT-based soft-tissue alignment should be considered in PTV margin design when 
using this method. 
 
Intraprostatic FMs continue to play an important role in increasing the accuracy of 
prostate IGRT, even with the advent of soft-tissue visualisation using CBCT.  FMs 
are likely to become increasingly important with the introduction of new 
technologies such as hydrogel spacers and kV intrafraction monitoring.
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Chapter 1: Introduction 
1.1. Chapter introduction 
Over the past few decades, external beam radiation therapy (EBRT) for prostate 
cancer has undergone significant advances.  Ongoing improvements in EBRT 
planning and delivery have allowed treatments to more closely conform to the 
targeted prostate and also minimise radiation dose to nearby healthy organs.  The 
ability to “escalate” radiation dose delivery to the prostate has subsequently resulted 
in improved treatment outcomes(1-5), yet also increases the risk of treatment-related 
toxicity.(1, 6)  Safe, effective EBRT for prostate cancer must balance the competing 
interests of achieving maximal tumour dose while also limiting dose to the adjacent 
normal tissue, such as the rectum and bladder. 
 
Several new technologies have significantly influenced EBRT practice over the past 
few decades.  These new technologies have included computed tomography (CT), 
three-dimensional planning, multi-leaf collimators (MLCs), electronic portal 
imaging devices (EPIDs), and more recently in-room volumetric imaging.  They 
have resulted in an improved ability to individualise radiation dose delivery by 
allowing more accurate shaping of the radiation beam along with the ability to 
visualise internal patient anatomy before and during treatment delivery.  The use of 
these new technologies has given rise to the concepts of intensity-modulated 
radiation therapy (IMRT) and image-guided radiation therapy (IGRT). 
 
As with any other therapeutic agent, the greatest challenge for radiation therapy is to 
achieve maximum chance of cure with the least morbidity.  Therefore, considerable 
effort has focussed on utilising new technology to reduce treatment-related toxicity 
while achieving higher tumour doses, for example using IMRT.  IMRT provides 
steep dose gradients and a high degree of conformality around the target which has 
improved the ability to avoid normal tissue and has subsequently decreased toxicity 
with respect to conventional radiation therapy.(7)  The precise nature of IMRT may 
increase the potential for underdose of the targeted prostate as steep dose gradients 
and tight safety margins increase the risk of geographic miss.   
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Parallel to advances from IMRT, prostate radiation therapy has benefitted from a 
greater understanding of organ motion and the integration of IGRT technology with 
treatment units.  It is well established that the prostate is mobile within the pelvis 
relative to bony anatomy and the position of the prostate relative to the rectum and 
bladder can also vary.(8, 9)  Treatment localisation has subsequently evolved from 
simple alignment of bony anatomy to more advanced tracking of the prostate using 
surrogates, such as implanted fiducial markers (FMs)(10-12), or direct visualisation 
of the gland with volumetric imaging, such as CT(13). 
 
As IGRT has been introduced into clinical practice, the role of radiation therapists 
(RTs) has undergone dramatic change.(14)  RTs have become increasingly 
responsible for autonomous provision of IGRT, often requiring complex decision-
making within a limited time.  There have been numerous changes in the frequency, 
type, quality, review, and actioning of verification imaging.  There has been a 
significant shift from infrequent (e.g. weekly) imaging to daily verification.(15)  This 
has been largely facilitated by the replacement of film-based verification with EPIDs 
which allow immediate image review.  Electronic imaging has also improved image 
quality as tools have become available to manipulate images.  Further image quality 
improvements have been provided by integration of kilovoltage (kV) systems.  The 
ability to remotely correct treatment couch position has also streamlined the online 
nature of IGRT.  Daily pre-treatment verification of prostate position using planar 
imaging with implanted FMs is now recommended as standard practice.(16) 
 
More recently, volumetric imaging has emerged as an alternative method of prostate 
IGRT.(13)  Volumetric imaging is a particularly attractive form of IGRT since the 
visualisation of soft-tissue, including the prostate, may offer the opportunity to 
forego surrogates such as FMs.  The role of soft-tissue alignment with cone beam CT 
(CBCT) is, though, largely unproven.(16)  In light of the rapid changes in 
technology and clinical practice, it is important to evaluate and compare IGRT 
methods in order to determine the most appropriate form of guidance and offer an 
evidence-based IGRT service. 
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1.2. Thesis objectives 
1.2.1 Motivation 
The commencement of this study coincided with the acquisition of new linear 
accelerators (linacs) with integrated kV imaging at Radiation Oncology Mater Centre 
(ROMC).  The capabilities of the new hardware provided the impetus to investigate 
new IGRT solutions for prostate EBRT.  Until that time, ROMC had limited IGRT 
capability; the new linacs replaced two units which had no electronic imaging 
capability, instead relying on film-based verification (see Figure 1.1).  A further two 
linacs within the department incorporated ion-chamber EPIDs.  These ion-chamber 
EPIDs provided limited IGRT capacity due to poor image quality and limited spatial 
resolution.  An example of anterior and lateral orthogonal images acquired with the 
ion-chamber EPIDs for prostate localisation is shown in Figure 1.2. 
 
Figure 1.1 Photographs of (a) de-commissioned Varian 800c, and (b) replacement 
21iX linear accelerators.  The superseded model had no portal imaging capability 
while the new model has an integrated On-Board Imager (OBI) (Varian Medical 
Systems, Palo Alto, CA, USA) with planar and volumetric kV imaging capability. 
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Figure 1.2 Example of megavoltage portal images taken using ion-chamber EPID, 
circa 2007.  Images obtained, with permission, from Radiation Oncology Mater 
Centre. 
 
The availability of modern, integrated IGRT hardware resulted in the introduction of 
FM-based IGRT for prostate EBRT.  While new to ROMC, FMs were becoming the 
gold-standard for prostate IGRT nationally and internationally.  Figure 1.3 represents 
an example of anterior and lateral orthogonal planar kV images with FMs implanted 
in the prostate.   
 
Figure 1.3 Example of anterior and lateral planar kilovoltage images with three 
fiducial markers inserted in the prostate. 
 
Several factors can complicate the provision of FM-based IGRT.  There are 
considerable costs associated with providing the gold markers and the insertion 
procedure.  In some cases, patients are unwilling to undergo implantation and others 
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are ineligible, for example due to anticoagulant dependence.  There is also a risk of 
infection from the trans-rectal insertion procedure.(17-19)  .  Therefore, a cohort of 
patients is unable to benefit from FM-based IGRT, and an alternative method of 
correcting for prostate motion is required. 
 
The availability of CBCT at ROMC provided the potential for image-guidance based 
on visualisation of soft-tissue prostate, without the use of FM surrogates.  
Volumetric imaging may also be favoured due to the ability to visualise adjacent 
normal tissue such as the rectum and bladder.  An example of a CBCT image of the 
prostate can be seen in Figure 1.4.   
 
 
Figure 1.4 Example of kilovoltage cone beam CT image of the male pelvis (note 
fiducial markers present). 
 
The chief motivation of this research thesis is to compare the planar and volumetric 
imaging methods in terms of localisation agreement and also interobserver 
variability.  This will ultimately inform the appropriate use of prostate IGRT within 
our department and ensure the newly acquired hardware is utilised in a safe and 
efficient manner.  Therefore we have compared localisation of the prostate using two 
methods of IGRT: planar kV imaging with FMs; and soft-tissue alignment with kV 
CBCT.  An important consideration in this comparison is to ensure RTs are able to 
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confidently and consistently perform prostate localisation.  Ultimately, the goal of 
this investigation is to ensure the IGRT method for prostate EBRT at ROMC is 
accurate and reproducible, and provides high-quality treatment for all prostate EBRT 
patients, with or without the use of intraprostatic FMs. 
1.2.2. Research aims 
The aim of this thesis is to investigate whether soft-tissue prostate alignment with 
CBCT provides an equivalent means of IGRT compared with the use of planar kV 
imaging utilising FMs.  In order to effectively compare the planar and volumetric 
IGRT methods, two main assessments should be made(20): 
a) The repeatability of each of the methods; and 
b) Direct comparison of the localisation accuracy from each method. 
 
Therefore, the aims of the research are to: 
1. Compare the isocentre localisation results from soft-tissue alignment using 
CBCT with the localisation from alignment to FMs (Method comparison); 
2. Determine the consistency of RTs aligning to FMs on planar kV imaging 
(Interobserver agreement) 
3. Determine the consistency of RTs aligning to soft-tissue on volumetric kV 
CBCT imaging (Interobserver agreement) 
1.3. Thesis outline 
This thesis is structured as a Masters by Publication, a presentation of related 
published works.  Chapter 2 discusses the relevant literature, examining some of the 
rapid advances in prostate radiation therapy, and providing a background for prostate 
IGRT. Chapter 2 also presents methodological and statistical considerations for the 
published articles. 
 
Chapter 3, “Interobserver variability of radiation therapists aligning to fiducial 
markers for prostate radiation therapy”, examines the ability of RTs to consistently 
align FMs on planar imaging.  Chapter 4, “Assessment of cone beam CT registration 
for prostate radiation therapy: fiducial marker and soft-tissue methods”, examines 
the ability of RTs to consistently align to soft-tissue on CBCT.  It also compares the 
localisation position obtained from soft-tissue and FMs on CBCT. 
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The published articles which constitute Chapters 3 and 4 have received minor 
formatting changes for consistency with the rest of the thesis.  The references from 
each article have been incorporated into the single reference list at the end of the 
thesis. Numbering of headings, tables and figures has been altered to reflect the 
thesis presentation.  The figures and tables have been incorporated into the text. 
 
Chapter 5 synthesises the main findings which link the manuscripts.  It discusses the 
critical issues encountered during the preparation of this thesis and looks to the 
future directions relevant to this research.  Chapter 6 summarises the conclusions 
from the investigation.  
1.4. Publications 
This thesis is presented as a Masters by Publication.  There are two peer-reviewed 
articles which constitute the body of work.  There have also been three relevant 
conference presentations from this study: two oral presentations and an electronic 
poster. 
1.4.1. Journal articles 
Deegan T, Owen R, Holt T, Roberts L, Biggs J, McCarthy A, Parfitt M, 
Fielding A. Interobserver variability of radiation therapists aligning to 
fiducial markers for prostate radiation therapy. J Med Imaging Radiat Oncol 
2013; 57(4):519–23. 
 
Deegan T, Owen R, Holt T, Fielding A, Biggs J, Parfitt M, McCarthy A, 
Roberts L. Assessment of cone beam CT registration for prostate radiation 
therapy: fiducial marker and soft-tissue methods. J Med Imaging Radiat 
Oncol, 2015; 59(1):91-98. 
1.4.2. Conference presentations 
Oral presentation: “Radiation Therapist observer variability in the 
assessment of kilovoltage images for prostate radiation therapy”, Annual 
Scientific Meeting of Medical Imaging and Radiation Therapy (ASMMIRT), 
Adelaide, April 2011; 
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Oral presentation: “Radiation Therapist observer variability in the 
assessment of cone beam CTs for prostate radiation therapy”, North 
Queensland Multi-Modality Conference, Townsville, August 2011; 
 
Electronic poster: “An assessment of cone beam CT soft-tissue-based 
localisation for prostate radiation therapy”, 12th International Conference on 
Electronic Patient Imaging (EPI2k12), Sydney, March 2012. 
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Chapter 2:  Background and literature 
review 
2.1. Chapter introduction 
Radiation therapy has been the subject of intense research and development over the 
past few decades.  Technological advances have resulted in significant 
improvements in treatment design, delivery and verification, particularly in the field 
of prostate radiation therapy.  The complexity of prostate radiation therapy has 
increased rapidly as treatments have increasingly aimed to maximise tumour dose 
and minimise unwanted dose to normal tissue.  Advances in IGRT have been at the 
centre of this increasing complexity.  In only a few years, IGRT technology has 
evolved from poor quality film, to electronic portal-imaging, to high-resolution 
volumetric imaging of soft-tissue with CT at the time of treatment. 
 
Numerous IGRT modalities are available for daily localisation of the prostate.  This 
thesis compares the localisation using two of the most common image-guidance 
techniques, planar kV and CBCT using a cohort of prostate cancer patients.  The 
examination also assesses the RTs’ interobserver variability with each imaging 
modality in order to better understand the most appropriate application of IGRT. 
2.2. Prostate anatomy 
Situated deep within the male pelvis, the healthy prostate is a walnut-sized gland 
located adjacent to the urinary bladder and rectum, see Figure 2.1.  The prostate 
envelops part of the urethra, a narrow tube which carries urine out of the bladder to 
the penis.  Part of the male reproductive system, the prostate’s main function is to 
secrete a milky white fluid that forms a large portion of seminal fluid which carries 
sperm.  The proximity of the rectum and urinary bladder, as shown Figure 2.1, is 
highly relevant to prostate radiation therapy. 
 
The prostate can be divided into four zones: the peripheral, central, transition, and 
anterior fibro-muscular zones.  The peripheral zone constitutes the posteriolateral 
aspect of the prostate, and comprises the majority of prostatic glandular tissue.(21, 
22)  The zonal boundaries are largely indistinct in young men, but significant 
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changes occur as men age and benign prostatic hyperplasia causes the transition zone 
to enlarge and dominate the prostate.(23) 
 
Figure 2.1: Sagittal view of male pelvic anatomy, demonstrating the position of the 
prostate within the pelvis and the proximity with the bladder and rectum. 
(Picture taken from anatomisty.com/male-anatomy/male-reproductive-organs-
2/attachment/male-reproductive-organs-2/ on 10th October 2013) 
2.3. External beam radiation therapy for prostate cancer 
Prostate cancer accounted for 33 % of newly diagnosed cancers among males in 
Australia in 2009.(24) Only non-melanoma skin cancers are more frequently 
diagnosed in Australia.  In 2010, 19,821 new cases of prostate cancer were 
diagnosed in Australia. The incidence of prostate cancer is steadily increasing, with 
estimations of 25,310 new prostate cancer cases in 2020 in Australia.(25)  The age-
standardised incidence of prostate cancer has increased over time, from 79 new cases 
per 100,000 males in 1982 to 194 per 100,000 in 2009.(24)  Tremendous advances in 
diagnosis and therapy have meant that while prostate cancer incidence has increased, 
relative survival has markedly improved from 58.2 % in the period between 1982 
and 1987 to 92.0 % in 2006-10.(26) 
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Active treatment options for localised prostate cancer include: 
 Surgery; 
 Radiation therapy; 
o External bean radiation therapy (EBRT); 
o Brachytherapy; 
 Hormonal therapy; and 
 Active surveillance. 
 
The choice of treatment modality is based on several factors, such as initial prostate-
specific antigen (PSA) level, the clinical stage of disease, and Gleason score.  
Consideration is also given to baseline urinary function, comorbidities and patient 
age.  While brachytherapy and active surveillance have become more prominent 
options in recent times, surgery and EBRT remain the most common forms of 
treatment.(27)  Although not all patients require therapy, active treatment of prostate 
cancer has been shown to offer a survival advantage.(28) 
 
Radiation therapy is one of the primary forms of treatment for prostate cancer.  The 
main principle of radiation therapy is to deliver sufficient dose of radiation to 
achieve tumour control while minimising dose to the neighbouring normal tissues, or 
organs-at risk (OARs).  EBRT is a widely established treatment option for prostate 
cancer, particularly for intermediate- and high-risk disease.  Considerable effort to 
improve outcomes from prostate EBRT has resulted in significant advances over 
recent decades.  In the 1990s, conventional prostate radiation therapy was associated 
with significant rates of local relapse, leading to a high risk of distant metastases and 
relatively poor survival.(2, 4, 29)  Improvements in prostate EBRT have focussed on 
increasing control rates while simultaneously decreasing treatment-related toxicity. 
2.3.1. Technical advances and dose-escalation in prostate EBRT 
In the 1980s and 1990s, radiation therapy was revolutionised by the introduction of 
technological advances including CT scanning(30), MLCs driven by computerised 
algorithms(31), as well as new computerised treatment planning systems which 
utilised features such as beams-eye-views (BEVs) digitally reconstructed 
radiographs (DRRs) and dose-volume histograms (DVHs)(32-34).   
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Until such advances, conventional prostate EBRT was limited to two-dimensional 
design. Radiation therapy treatment plans typically consisted of few beams arranged 
in opposed pairs or four-field boxes.  The treatment beams were often unshaped 
rectangular treatment portals which inevitably included large volumes of normal 
tissue as well as the targeted prostate.  Such treatment resulted in significant risk of 
late side-effects, such as rectal bleeding, therefore limiting therapeutic doses to 60-
70 Gy.(29, 35)  Technological advances in the 1990s saw the introduction of three-
dimensional conformal radiation therapy (3DCRT), which utilised CT-based 
planning and conformal shielding.(34, 36)  Introduction of 3DCRT resulted in 
improved delineation of the prostate using CT, more accurate dose calculations and 
increased conformality of dose delivery.  These factors combined to improve 
avoidance of OARs in treatment design. 
 
Several randomised controlled trials (RCTs)(6, 29, 37) and historical series(2, 38) 
have subsequently evaluated dose-escalated prostate EBRT using photons.  
Interpretation of many dose-escalation studies is complicated by changes in 
diagnosis, staging, and therapy over the period since initial accrual, yet their results 
are strongly in favour of the advantage of dose-escalation. The results of three major 
randomised dose-escalation trials are summarised in Table 2.1.   Increasing the 
prescribed dose has been shown to increase biochemical control(1, 39, 40), reduce 
distant metastases(2, 4), and improve cause-specific survival(4).  No direct evidence 
of improved overall survival has, as yet, been obtained from RCTs studies.(40) 
Epidemiological data has, though, shown that prostate cancer survival continues to 
improve.(26) 
 
Table 2.1: Summary of prostate EBRT dose-escalation RCTs 
Trial Conventional dose (n) 
Escalated 
dose (n) 
Median FU 
(months) 
Significant 
improvements 
(p ≤ 0.05) 
No difference 
(p > 0.2) 
M.D. 
Anderson (39) 
 
70 Gy 
(150) 
78 Gy 
(151) 104 
BCF 
CF OS 
MRC RT01 
(41) 
64 Gy 
(421) 
74 Gy 
(422) 120 BCF OS 
Dutch group 
(40) 
68 Gy 
(331) 
78 Gy 
(333) 110 
BCF 
LF 
CF 
DM 
PCD 
OS 
n, number of patients; BCF, biochemical or clinical failure; CF, clinical failure; LF, local failure; 
OS, overall survival; DM, distant metastasis; PCD, prostate cancer death 
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A meta-analysis of dose-escalation RCTs concluded that dose-escalation should be 
offered to all patients undergoing definitive prostate EBRT regardless of their 
disease risk status in order to reduce the risk of recurrence.(42) 
2.3.2. Prostate radiation therapy-related toxicity 
While the above studies confirmed that dose-escalation can improve prostate disease 
control, they also demonstrated that raising the prescribed dose caused increased 
toxicity, especially to the rectum.  Dose-escalation has been shown to significantly 
increase the likelihood of gastrointestinal (GI) toxicity.(1, 39, 43)  Retrospective 
analysis indicated that GI toxicity could be reduced by limiting the amount of rectum 
irradiated.(37)  Conversely, no dose-escalation trial has demonstrated statistically 
significant increases in genitourinary (GU) toxicity with increasing dose.(1, 37, 39, 
43, 44)  The Dutch trial suggested it is likely that GU toxicity is under-reported since 
GU symptoms require particularly long-term follow-up. 
 
While it can be generalised that higher prescription dose will by definition equate to 
increased toxicity, there are measures to reduce the risk.(40)  In order to facilitate 
dose-escalation, it has become obvious that limiting the amount of normal tissues 
included in the treatment volume is required.  IMRT has emerged as a useful means 
to this end. 
 
Dose-escalation studies have resulted in a better understanding of the dose-response 
of the prostate and OARs.  Toxicity data has informed appropriate dose-volume 
constraints to minimise side-effects.(45)  It is believed that further dose-escalation is 
required to achieve continued improvements in control rates, either by prescribing 
above 80 Gy(42, 46) or by hypofractionating dose in fewer fractions(47).  In order to 
continue dose-escalation, techniques which improve rectum sparing, such as IMRT, 
have been required.(37) 
 
As its name suggests, IMRT essentially splits the treatment field into numerous 
“beamlets” which can each have their own intensity of radiation dose.  This allows 
the overall treatment field to consist of areas of high and low intensity to better 
control the dose delivered.  The modulation of dose within treatment fields presents 
almost limitless ability to sculpt radiation dose around targets and OARs.  The 
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widespread introduction of IMRT has resulted in more complex field shaping and 
greater conformality of dose delivery to the targeted prostate. Importantly, this has 
also led to improved sparing of the OARs. 
 
IMRT enables steep dose-gradients between the target and adjacent OARs.  In the 
case of prostate IMRT, this is intended to achieve high target doses with improved 
sparing of the rectum and bladder.  IMRT is often used to achieve higher target doses 
and/or reduced OAR dose compared with 3DCRT.(7, 48-50)  IMRT is generally 
unable to reduce the risk or severity of GU toxicity, most likely because the bladder 
neck and inferior portion of the bladder trigone remains in the high-dose portion of 
the planning target volume (PTV).(7, 49, 50) 
2.3.3. The risk of geographic miss in prostate EBRT 
The risk of geographic miss and subsequent systematic underdose of the target has 
been increased with the use of IMRT, due to the associated steep dose gradients and, 
in many cases, tight PTV margins.  Compounding this risk is the uncertainty due to 
prostate organ motion secondary to variable filling of the rectum and bladder 
(discussed in detail in following section).  Even in the pre-IMRT era, the risk of 
geographic miss was shown to be high by de Crevoisier et al. and Heemsbergen et 
al.(51, 52)  A reduction in biochemical control of about 30 % at five years was found 
by de Crevoisier et al. when the rectum was distended at simulation compared to the 
time of treatment.(51)  The results suggest that the rectum was often empty during 
treatment due to treatment-related effects, such as diarrhoea.  Therefore, a distended 
rectum at simulation was not representative of the anatomy over the course of 
treatment.  Without IGRT, these errors could not be corrected and the prostate was 
likely to shift posteriorly, outside the high-dose region.  In order to minimise the risk 
of geographic miss, it is important to understand treatment-related uncertainties and 
perform accurate target localisation prior to treatment delivery, for instance using 
IGRT. 
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2.4. Uncertainties in prostate EBRT  
2.4.1. The nature of systematic and random errors 
Inevitably there are several types of errors or uncertainties involved in the planning 
and delivery of EBRT.  Such errors can generally be categorised into systematic (Σ) 
or random (σ) errors.   Systematic errors can be broadly regarded as treatment 
preparation errors, affecting all fractions.  Systematic errors have the effect of 
shifting the overall dose distribution.  Random errors are those broadly regarded as 
treatment execution errors, affecting each fraction individually.  The effect of 
random errors is different to that of systematic, as they act to blur the dose 
distribution. 
 
Types of uncertainty within EBRT include: 
 Delineation uncertainties: e.g. due to inter- and intra-observer variations, affected 
by image quality and modality; 
 Phantom-transfer errors: systematic uncertainties from the transfer of information 
between systems such as from the CT to the planning system, to the record-and-
verify system, to the linac; 
 Patient setup variability: e.g. due to the variable relationship of external setup 
marks (such as tattoos) and internal anatomy; 
 Interfraction organ motion: e.g. displacement, including translation and rotation, 
of the internal organs between fractions; 
 Intrafraction motion: e.g. organ motion from patient movement, respiratory 
motion, cardiac motion or peristalsis; 
 Anatomic changes: e.g. deformation due, for example, to tumour response 
growth or oedema; 
 Image-guidance errors: e.g. from finite resolution of IGRT system, residual 
couch correction errors; 
 Delivery uncertainties: e.g. dose calculation uncertainties, multi-leaf collimator 
(MLC) motion uncertainty. 
 
IGRT aims to reduce, but cannot eliminate, the errors associated with EBRT.  IGRT 
is most effective in reducing setup and organ motion errors.  A level of residual 
uncertainty will always remain after attempts to correct known errors.  For instance, 
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IGRT cannot eliminate delineation errors.  Any limitations inherent in the IGRT 
method will also produce additional uncertainties (e.g. intra- and interobserver 
variation as well as the latency between image acquisition and treatment).  The 
presence of intrafraction motion or target deformation is difficult to correct with 
current technology.  Additionally, the process of correcting patient position by 
adjustment of the treatment couch will have some level of inaccuracy.  Subsequently, 
the use of a safety margin is required to account for these errors. 
2.4.2. Volumes and associated margins 
The International Commission on Radiation Units and Measurements (ICRU) 
established standard terminology for the creation of margins over twenty years ago 
(53), and continues to refine them as technology advances(54, 55).  ICRU definitions 
of the volumes used in margin creation can be summarised as: 
 Gross tumour volume (GTV): the primary tumour volume.  Can be defined on a 
variety of imaging modalities, including pre-operative series. 
 Clinical target volume (CTV): includes GTV and possible microscopic disease 
(subclinical involvement).  The CTV should include a margin for delineation 
error in the definition of the GTV. 
 Internal target volume (ITV): a component of the PTV, this additional margin is 
required to account for potential variations in CTV position, shape and/or size.  
This includes inter- and intrafraction variation.  This internal margin includes an 
expansion  to account for variations due to organ  motion from, for example,  
respiration or peristalsis.  It should be noted that this volume is not defined 
explicitly, but is incorporated in next stage. 
 Planning target volume (PTV): consists of the above GTV, CTV and ITV.  Also 
includes the setup margin which is intended to account for geometric errors 
between planning and treatment.  Essentially, the PTV is a geometric construct 
which serves to ensure that an adequate dose will be delivered to all parts of the 
CTV (within a clinically acceptable probability). 
 Planning organ-at-Risk volume (PRV): margin around OARs to account for set-
up uncertainty and changes in their position, shape and size.  The proximity of 
OARs to the targeted tissue can have an influence on PTV design, whereby target 
margins are minimised to avoid overlap with the OAR. 
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Figure 2.2: Schematic of the relationship between the different volumes used in 
radiation therapy under various clinical scenarios (Source: ICRU Report 62 (54)). 
 
While the ICRU reports defined the volumes required for safe EBRT, they did not 
specify how these margins should be calculated.  In many clinical situations, margins 
have been created based on clinical experience, for example a 7-10 mm fixed margin 
about the prostate.  In prostate EBRT, the posterior margin has often been made 
smaller than other directions to reduce the overlap with the rectum.  There are 
numerous statistically derived margin recipes available which can be used to 
calculate treatment margins.  The formula created by van Herk et al.(56) has been 
widely adopted.  It has been derived to ensure that 90 % of the patients in a 
population receive a minimum cumulative dose to the CTV of at least 95 % of the 
prescribed dose: 
ܯ ൌ 2.5ߑ ൅ 0.7ߪ 
where ܯ is the margin, and ߑ and		ߪ are the SDs of the systematic and random errors 
of the patient group respectively. 
 
One of the major limitations with margin recipes is that they are population-based, 
and over- or underestimate margins required for individual patients.  IGRT has the 
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potential to allow customisation of margins to suit each individual patient’s 
characteristics.  The use of IGRT to accumulate information over several fractions to 
monitor and optimise treatment has been dubbed adaptive radiation therapy (ART).  
Adaptation of the treatment plan with greater individualised knowledge has been 
investigated to reduce treatment margins and compensate for anatomical changes 
during treatment.(57, 58)  Reduction in uncertainties (e.g. setup errors and organ 
motion) may allow reduction of PTV margins. 
2.4.3. Setup error 
Setup errors have both a systematic and random component and can be classified as 
the difference in the planned and treated patient position, with respect to bony 
anatomy.  The variability of setup for prostate EBRT has been reported extensively.  
Setup errors can be minimised with attention to patient positioning and correction 
strategies.(59-63)  Ensuring patient comfort can assist, as can reducing the treatment 
time (i.e. the amount of time the patient is required to remain still, including time for 
image acquisition, analysis and action).  Setup errors can be accounted for by the use 
of an EPID to image bony anatomy and correct displacements from the planned 
position with use of an online or offline correction strategy.(63, 64) 
2.4.4. Interfraction prostate organ motion 
Historically, prostate position was predicted by alignment to skin marks and bony 
anatomy.  It is now evident that the prostate position varies with respect to these 
landmarks.  Assessment of the stability of the prostate with respect to bony anatomy 
has been performed using various techniques, such as FMs(65-70), multiple CT 
scans(59, 71-79), and ultrasound(80-82). 
 
Due to significant differences in the design of prostate organ motion studies, direct 
comparison of their results is difficult.(8, 9)  Variations in study design include: 
 Choice of surrogate for prostate position (FMs, CT, or U/S); 
 Rectal and bladder filling status; 
 Patient position (supine or prone); 
 Frequency of measurements; and 
 Use of immobilisation and positioning devices. 
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Many of the prostate motion studies involved interventions at simulation which were 
not repeated at subsequent sessions, such as use of enema or introduction of contrast.  
Regardless of methods, these studies have clearly demonstrated that skin marks and 
bony anatomy are poor surrogates of prostate position.  Table 2.2 is a summary of 
selected interfraction prostate motion studies. 
 
Table 2.2:  Summary of literature reporting one standard deviation (SD) interfraction 
prostate displacement relative to bony anatomy 
 
Variability of prostate position between treatment fractions has been shown to be 
most pronounced in the anterior-posterior (AP) and superior-inferior (SI) directions, 
while the prostate is most stable in the left-right (LR) direction.(67, 75, 77, 83)  
Quantification of motion has indicated that variable prostate positioning is highly 
correlated with differences in rectal size and, to a lesser extent, bladder filling.(59, 
65, 71-75, 77, 84, 85)  Several studies of prostate motion have concluded that daily 
localisation of the prostate is required to correct for the large, unpredictable prostate 
Study Pts Modality Surrogate 
1 SD displacement 
(mm) 
SI LR AP 
van Herk, 
1995(59) 11 
Repeat CTs: Simulation 
& weeks 2, 4, 6 Contours 2.4 1.3 3.8 
Roeske, 
1995(72) 10 Weekly CT Contours 3.2 0.7 3.9 
Althof, 
1996(67) 9 Planar kV (simulator) 
125I seeds 1.7 0.8 1.5 
Rudat, 
1996(74) 28 
CT (single 8mm axial 
slice)  N/A 1.9 3.7 
Melian, 
1997(75) 13 CT  3.1 1.2 4.0 
Vigneault, 
1997(68) 11 EPID Single apical FM 3.6 1.9 3.5 
Antolak, 
1998(76) 17 
Repeat CTs:  Simulation 
& weeks 2, 4, 6  3.6 0.9 4.1 
Stroom, 
1999(78) 
 
15 Repeat CTs:  Simulation & weeks 2, 4, 6 
Contoured CTV on 
each CT (Chamfer 
matched to bones) 
2.8 0.6 2.8 
15 Repeat CTs:  Simulation & weeks 2, 4, 6 
Contoured CTV on 
each CT (Chamfer 
matched to bones) 
1.7 0.5 2.1 
Zelefsky, 
1999(77) 50 
Repeat CTs:  Simulation, 
day 1, week 4,  and last 
week 
Contoured CTV on 
each CT (Chamfer 
matched to bones) 
3.3 0.8 2.9 
Wu,  
2001(69) 13 EPID FMs 2.1 N/A 2.3 
Frank, 
2008(79) 15 
Simulation CT & 3/week 
CT (CT-on-rails) Contours 2.9 0.9 4.1 
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motion using methods such as implanted FMs as a surrogate of prostate position.(65, 
66) 
2.4.5. Intrafraction prostate organ motion 
Prostate motion during the treatment session (intrafraction motion) has been 
quantified by various means, including imaging FMs before and after treatment(86-
90), as well as use of cine-MRI(91-93), U/S(94), and electromagnetic 
transponders(95-97).  While the prostate can be very stable during a treatment 
session, there are two main types of motion possible.(95-97)  The prostate has been 
observed to slowly drift in position, possibly due to relaxation of the pelvic muscles.  
Otherwise, transitory motion, associated with peristaltic motion, has been described 
where the prostate shifts a large distance (often >10 mm) but returns close to its 
original position within a short time period.(97)  Similar to interfraction motion, 
shifts are most evident in the SI and AP directions.  Intrafraction prostate motion has 
been shown to be correlated with rectal motion, and can exceed 10 mm.(91, 92)  
Less intrafraction motion was found compared with interfraction variations.(93) 
 
It has been generalised that intrafraction motion is inconsequential compared with 
interfraction displacement.(92)  Yet, as correction for interfraction motion is readily 
achieved, the effect of intrafraction prostate motion has become increasingly 
relevant. The significance of intrafraction motion varies according to the nature of 
the movement. For conventionally fractionated treatments, short transitory motions 
are likely to have less dosimetric impact than a persistent drift.  The biggest impact 
of intrafraction motion is the unlikely event that short, transitory motion coincides 
with the timing of pre-treatment imaging.  Intrafraction monitoring has highlighted 
the benefit of reducing the treatment session time and commencing treatment as soon 
as possible after initial positioning.(97, 98)  It is important to minimise the time 
required for image acquisition and interpretation to reduce the likelihood of prostate 
motion away from the imaged position. 
2.4.6. Prostate deformation and rotation 
As well as shifting within the pelvis, the prostate is known to change size and shape, 
and rotate during a course of EBRT.  In early investigations of prostate volume 
changes, Roeske et al. found that for individual patients, the prostate and seminal 
vesicle volume can vary by ±20 % and -50-70 % respectively.(72)  Another study by 
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Roach et al. found that for individual patients, a 14 % median variation from the 
average prostate volume was detected, along with a 28 % average maximum 
variation between the largest and smallest prostate volumes.(99)  A comparison of 
the planning CT and another CT, repeated 2 week later, found the prostate decreased 
in volume by 14 % (averaged over all patients).  Subsequently, the prostate volume 
tended to stabilise.(99) 
 
Deurloo et al. delineated the prostate on multiple repeat CT scans and found that 
there were no significant variations in prostate volume during the course of 
EBRT.(100)  They concluded that deformation was sufficiently small that the 
prostate could be considered a solid-organ for the purpose of IGRT.  Multiple CTs 
were also used by van der Wielen et al. to determine prostate and seminal vesicle 
deformation.(101)  Variations were measured with respect to intraprostatic FMs.  
They found small  prostate deformation (SD < 1 mm), similar to the results of 
Deurloo et al.(100)  The seminal vesicle deformation, though, was considerably 
larger (SD ≤ 3 mm).  Nichol et al. examined variations in prostate size and shape 
relative to FMs using MRI.(102)  They found that the prostate exhibited shape and 
volume changes during treatment.  The prostate volume was observed to enlarge (by 
up to 34 %) on MRIs taken in the first half of EBRT.  On MRIs taken in the second 
half of treatment, the prostate was found to shrink (by up to 24 %) compared with 
the planned volume.  The distance between FMs also reduced over the treatment 
course.   
 
Changes in prostate rotation have also been investigated.  Hoogeman et al. 
performed several repeat CTs to quantify prostate motion, including rotation.(103)  
Large variations in the size of the rectum at planning were found to cause large 
systematic errors in prostate rotation about the LR axis (1 SD = 5.1°).  An adaptive 
approach, using the planning and four repeat CTs, was able to reduce the rotational 
error significantly.  Boda-Heggemann et al. measured prostate rotation relative to 
FMs.(104)  Variations in prostate tilt were correlated with AP displacement of the 
prostate, while the degree and angle of the tilt depended on the direction and 
magnitude of prostate motion.(104)  Posterior prostate motion was observed to cause 
a systematic tilt of 1°/mm.  Owen et al. measured prostate rotations using two 
methods: FMs and the prostate-rectum border as observed using CT-on-rails.(105)  
 Chapter 2:  Background and literature review 22 
 
Prostate rotation was found to be a significant source of error, which was more 
accurately measured using CT images. 
 
More recently, investigations have been performed to measure prostate rotation 
using implanted electromagnetic transponders.(106)  Prostate rotations were found to 
be much larger than deformation, with the potential to cause target underdose if not 
managed.  Despite correction for prostate displacement, 16 % of patients included in 
the study would have been underdosed when using a 5.0 mm PTV margin.  Amro et 
al. found that the dosimetric impact of prostate rotation varies on an individual 
patient basis.(106) 
2.4.7. Strategies to minimise prostate motion 
As outlined above, variations in rectal and/or bladder volume have been shown to 
alter the prostate position with the pelvis.  A common approach to reducing prostate 
organ motion, then, has been to reduce the daily variations of rectal and bladder 
filling.  Wu et al. postulated that instructing patients to control bladder and rectal 
filling may have led to smaller prostate motion than had been observed in other 
studies.(69) 
 
Roach et al.(107) and Pickett et al.(108) took the approach of acquiring planning 
CTs with a full bladder and empty rectum based on the expectation this would 
achieve the most posterior prostate position.  Subsequently, they applied relatively 
tight posterior margins with larger margins anteriorly to account for motion.  No 
attempt was made to control rectal filling at treatment, but patients were treated with 
a full bladder.  A follow-up study to validate the variable margin theory 
demonstrated posterior prostate motion was still likely, as well as systematic 
variation superior to the planned position.(99) 
 
Additional studies have also demonstrated that attempts to limit rectal variations 
have limited success in reducing prostate motion.  Kupelian et al. have shown that 
prostate motion is still evident despite an empty rectum at simulation.(109)  There 
are indications that controlling diet can decrease the incidence of rectal gas, and 
therefore prostate motion.(110)  Conversely, other studies have shown that the use of 
agents such as milk of magnesia to promote an empty rectum has little effect in 
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limiting inter- or intrafraction prostate motion.(111, 112)  Mechanical removal of 
bowel gas at the time of treatment has, though, been shown to decrease prostate 
motion.(113) 
 
An alternative approach has been to attempt to reproduce a distended rectum using 
endorectal balloons in order to minimise variation from the simulated rectal 
size.(114)  This is intended to reduce prostate motion secondary to variations in 
rectal size.  Additionally, the rectal balloon has the effect of moving a portion of 
rectum away from the prostate, allowing the posterior part of the rectum to be 
shielded from the high-dose region.(115) 
 
While it is recognised that prostate motion is more correlated with rectal variation 
rather than with differential bladder filling, it is also common to attempt to reproduce 
a consistent bladder volume.  Many clinical protocols prefer the bladder to be 
“comfortably” full during prostate EBRT. This state is probably more difficult to 
reproduce than an empty bladder, but it has benefit of shifting a portion of the 
bladder and small bowel away from the high-dose treatment region. Therefore, it 
could be argued that the desire for a full bladder volume is based on minimising 
bladder and small bowel toxicity as much as trying to reduce prostate motion. 
2.5. Prostate image-guided radiation therapy (IGRT) 
Despite attempts to reduce prostate motion, as outlined above, the prostate is highly 
mobile and it is important to identify and correct variations in target location at the 
time of treatment delivery.  This can be performed using various image-guidance 
methods. 
2.5.1. Image guided radiation therapy methods 
There are numerous IGRT modalities with the potential to more accurately guide 
treatment delivery for prostate EBRT.  The most common IGRT techniques utilise x-
rays either from the megavoltage (MV) treatment beam or a kV “diagnostic” source.  
The optimal IGRT solution for prostate EBRT is unclear, yet it should have certain 
attributes, such as accuracy and consistency across multiple operators and clinical 
situations.(116, 117)  Ideally, the IGRT solution would be minimally invasive, with 
low imaging dose and high patient tolerability.  It should also be efficient in terms of 
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additional workload required, including training and ongoing quality assurance.  It 
would also be desirable to have an IGRT solution which is transferable to other 
treatment sites. 
 
This section concentrates on the two modalities investigated in this thesis: 
 planar kV imaging (utilising FMs); and 
 kV CBCT. 
2.5.1.1. Planar IGRT using intraprostatic fiducial markers 
There can be significant prostate motion relative to bony landmarks. The traditional 
use of skin marks and portal imaging based on bony anatomy has been shown to lack 
the accuracy required to treat the prostate to therapeutic doses while maintaining 
appropriate margins to avoid excessive toxicity.  Unfortunately, the prostate lacks 
sufficient radiographic contrast with adjacent structures to be visible on planar 
radiographic imaging.  Therefore, implantation of radio-opaque FMs, acting as a 
surrogate of prostate position, has become one of the most widely adopted 
techniques for prostate localisation. 
 
The most commonly used FMs for prostate EBRT are small gold seeds 
(approximately 0.8 to 1.0 mm diameter and 3.0 to 5.0 mm length). The inert, radio-
opaque nature of gold makes it an ideal substance for implantation.  Generally, three 
FMs are considered to act as surrogate for the positioning of the solid organ 
prostate.(118)  Some of the earliest documented uses of implanted markers in the 
prostate are from Sandler et al.(119) and Shipley(120). 
Implantation of FMs 
FMs are typically inserted into the prostate using trans-rectal ultrasound (TRUS) 
guidance in a manner similar to that of diagnostic biopsy.(18, 121, 122)  Patients are 
required to cease anticoagulant medication approximately one week prior to 
implantation.  Generally, patients are provided with antibiotic prophylaxis prior to 
and during the procedure.  An enema preceding the implantation is recommended to 
empty the bowel in order to improve ultrasound visualisation and also reduce the risk 
of infection.  The use of anaesthetic, such as nerve block, is not universal, but 
depends on local protocols.  Generally, three sterilised FMs are triangulated within 
the prostate: at the prostate base, apex and mid-gland.(12, 123) 
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Figure 2.3: Example of fiducial marker used within this thesis (0.9 x 3.0 mm CIVCO 
Acculoc) 
 
 
Figure 2.4:  Schematic diagram of implantation of fiducial markers via trans-rectal 
ultrasound guidance. 
(Picture taken from: www.cancer.gov/images/cdr/live/CDR446226-750.jpg on 10th 
October 2013) 
 
An alternative approach is transperineal implantation which, despite a lack of firm 
evidence, is regarded as having a relatively lower infection risk.(124)  Transperineal 
implantation may, though, require additional anaesthesia.(124, 125) 
Clinical application of intraprostatic FMs 
Intraprostatic FMs have been used to quantify prostate organ motion.(65, 66)  The 
resultant understanding of prostate motion gave rise to protocols which used FMs to 
 Chapter 2:  Background and literature review 26 
 
correct displacement on a daily basis.(10, 11) Technological innovations in EPID 
and treatment couch hardware were important in enabling daily IGRT for prostate 
EBRT.  The advent of high-resolution amorphous silicon (a-Si) EPIDs resulted in the 
ability to image fine diameter FMs with the MV treatment beam.(11, 126)  The 
ability to remotely adjust the treatment couch also facilitated immediate (on-line) 
correction of prostate displacements.(127)  One of the chief advantages of FM-based 
IGRT is the ease of matching markers on planar imaging.(126)  Daily, on-line 
correction of prostate motion with FMs, in conjunction with MV or kV planar 
imaging, has subsequently been widely implemented.(11, 12, 68, 69, 123, 126, 128-
134) 
 
Daily on-line correction for prostate motion based on FMs is able to account for 
interfraction organ motion and patient setup uncertainties (i.e., both systematic and 
random error components).  It is important to note that residual errors remain due to 
factors such as delineation uncertainty, phantom transfer errors, finite resolution of 
the imaging system, couch correction uncertainty and intrafraction motion errors.  
Therefore, even with a daily on-line correction protocol, a PTV margin is required. 
FMs:  risks and complications 
Insertion of FMs under TRUS-guidance is regarded as safe and well tolerated, yet it 
is not without risks and complications.(17-19)  Langenhuijsen et al. reported 
minimal complication rates despite use of relatively large FMs (1.0 x 7 mm).(18)  
Follow-up of 209 men undergoing the TRUS implantation procedure found 6.2 % 
had moderate complication from pain and fever, which was resolved with oral 
medication.  Other reported complications included voiding difficulty (1.9 %), 
haematuria for > 3 days (3.8 %), haematospermia (18.5 %), and rectal bleeding (9.1 
% cases).  Shinohara et al. reported only one of 705 patients implanted with gold 
FMs developed a urinary tract infection (UTI) requiring antibiotic treatment.(121)  
This assessment required patients to report unexpected or severe complications 
following the procedure and therefore may be underestimated.   
 
İğdem et al. found that men undergoing TRUS insertion of FMs reported less pain 
than was associated with their biopsy procedure.(17)  No major toxicities requiring 
intervention were reported.  Haematuria, rectal bleeding and fever were reported by 
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15 %, 4 % and 2 % of patients respectively.  Gill et al. surveyed patients who had 
previously undergone TRUS-guided insertion of FMs and found that 32 % of 
patients experienced at least one symptom, such as urinary frequency, haematuria, 
dysuria, rectal bleeding, and haematospermia.(19)  Significantly, three patients 
required hospital admission for infectious complications, including a case of Grade 4 
sepsis with E. coli resistant to both ciprofloxacin and gentamycin.  The survey 
results indicated that unless specifically sought, complication rates are probably 
underreported, as many of the complications identified in the survey had never been 
otherwise reported to the department despite the expectation for patients to do 
so.(19) 
 
Berglund et al. reported infection risks following insertion of electromagnetic 
transponders.(135)  An assessment of 50 patients found five developed infectious 
complications, and three required antibiotic treatment for UTI.  Two patients 
developed significant infectious complications, including one who developed a 
prostatic abscess with methicillin-resistant bacteria and subsequently died of an 
unrelated lower GI bleed.   
 
There is evidence that infectious complications following TRUS biopsy are 
increasing in incidence.(136)  Of particular concern is the emergence of infections 
complicated by multi-drug resistant Escherichia coli.  Patients undergoing TRUS 
insertion of FMs may be at particular risk since they have previously been exposed 
to quinolone antibiotics during their diagnostic biopsy.  They are subsequently at 
elevated risk of infection from the resistant bacteria.  A further complication with 
insertion of FMs is the requirement for patients to cease anti-coagulants 
approximately one week prior to the procedure.  This results in some patients 
becoming ineligible for FMs and subsequently unable to undergo FM-based IGRT. 
 
While the risks associated with TRUS insertion of FMs may be generally regarded as 
minimal, it has been shown that significant morbidity can result from the procedure.  
Therefore, it is worth investigating alternative IGRT methods which could eliminate 
the need for FMs. 
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FMs as a prostate surrogate 
The underlying premise of using FMs as a surrogate of prostate position is that the 
markers represent the position of the prostate over the entire course of treatment.  
The accuracy of FMs as a surrogate of prostate motion has been questioned with 
respect to the potential for seed migration, as well as their ability to demonstrate 
prostate rotation and deformation.  It is important, then, that the FMs do not move 
appreciably within the prostate and the size and shape of the prostate should be 
stable throughout the treatment course. 
 
Numerous investigations have focussed on establishing the appropriateness of FMs 
as a surrogate of prostate position by measuring the distance between individual FMs 
over time.  In a small patient series, Shirato et al. demonstrated significant in-
migration of intraprostatic FMs in five out of six patients, consistent with a mean 
rate of volume decrease of 9.3 % in ten days.(137)  A number of other studies have 
also shown variations in intermarker distances.(69, 126, 128, 138, 139)  However, 
several other studies have shown that the FMs remain relatively stable over a course 
of treatment.(129, 131, 140) 
 
In the most comprehensive assessment of intermarker distances, Kupelian et al. 
assessed 56 patients with three intraprostatic FMs (2,037 daily alignments).(141)  
Very few markers (2/168) were found to undergo a significant change in relative 
position, and the variation was attributed to prostate deformation rather than marker 
migration.(141)  Kupelian et al. recommended the use of the centre-of-mass of the 
three FMs to reduce the uncertainty due to variations of individual markers.(141)  
They concluded that FMs are a reliable means of prostate localisation, even in the 
presence of prostate deformation. 
 
Another study of inter-marker distances during a course of EBRT  by van der Heide 
et al. indicated an initial small increase in inter-marker distance followed by a 
reduction of about 4 % during treatment (average 0.9 mm change).(132)  The authors 
speculated that such variations between FMs may be due to oedema at the initiation 
of EBRT and then gradual prostate shrinkage as treatment progresses.  While small 
inter-marker distances were identified, it was suggested that the effect of determining 
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the centre-of-mass of the FMs was minor (by a factor of 1/√2).  Use of more than 
two FMs was recommended to further reduce this uncertainty. 
 
Nichol et al. found that during a course of EBRT, the prostate shrank and changed 
shape, i.e. deformed.  The distance between FMs also reduced over time.(102)  Since 
patients only underwent one MRI during the treatment course, the study lacked 
sufficient data to map the precise timeline of prostate volume changes.  The authors 
found that, on rare occasions, patients could undergo large variations in prostate size 
and shape which daily imaging of FMs could not detect.  It was suggested that soft-
tissue imaging, such as with CBCT, was required to detect and correct such prostate 
deformations.(102) 
 
Prostate rotations have been assessed by Owen et al. using FMs and soft-tissue-
guidance with CT-on-rails.  Volumetric imaging was  shown to determine prostate 
rotation more accurately than FMs.(105)  The ability of FMs to demonstrate prostate 
rotation was affected by the position and proximity of implantation. 
 
In summary, the literature suggests FMs are a good surrogate for the position of the 
prostate.  In the presence of rotation or deformation of the prostate, FMs are less able 
to predict the prostate position.  CBCT may be better able to monitor and therefore 
correct prostate rotations and deformation than FMs.  Soft-tissue visualisation with 
CBCT has the benefit of allowing assessment of changes in prostate volume as well 
as position. 
Economic implications of FMs 
There are several financial implications when adopting FMs for IGRT, such as the 
cost of FMs themselves and the costs associated with the TRUS insertion procedure.  
The impact on workload of the IGRT process also has financial implications. 
 
The cost of supplying FMs can be prohibitive, especially due to the large number of 
patients requiring prostate EBRT.  At least one Australian centre found 
commercially available FMs were too expensive and subsequently developed their 
own markers.(12)  Within the Australian healthcare setting, the cost of FMs is borne 
by either departments or patients since the FMs are not currently reimbursed by the 
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Medicare Benefits Schedule (MBS), while the insertion procedure is funded under an 
interim arrangement.  Funding arrangements for FMs and the TRUS insertion are 
currently under review by the Medical Services Advisory Council (MSAC), pending 
a larger review of IGRT and IMRT.(142) 
 
An assessment of the cost-effectiveness of prostate IGRT has been performed by the 
Trans-Tasman Radiation Oncology Group (TROG).(143)  It found that IGRT (with 
either planar imaging using FMs or volumetric imaging) was more costly than non-
IGRT methods due to the additional expense of supplying FMs and the additional 
imaging time required per treatment session.  Ultimately, though, the investigation 
found these costs would be offset by a reduction in radiation-related toxicity due to 
use of IGRT.  Cost-effectiveness of IGRT was found to be enhanced by facilitating 
the use of IMRT which potentially reduces treatment-related toxicity. 
 
Improvements in IGRT technology have gradually increased the cost-effectiveness 
of the procedure.  Improvements such as remote-couch and planar kV imaging, 
compared with MV EPID, are able to decrease the time required for a treatment 
fraction.(144)  While the initial cost of advanced IGRT technology is substantial, it 
was found to be offset by ongoing savings due to improved efficiency.  The cost per 
fraction is reduced by use of planar kV imaging compared with traditional MV EPID 
imaging.(144) 
2.5.1.2. Prostate IGRT using CT 
Radiation therapy treatment planning evolved from planar to volumetric imaging 
with the advent of 3DCRT in the 1990s.  There is currently a similar evolution 
occurring in the field of IGRT.  The emergence of in-room CT options has presented 
a viable alternative to planar techniques.  The important point of difference between 
planar and volumetric imaging is the ability to directly visualise soft-tissue.  While 
planar imaging relies on surrogates to define the prostate position, CT offers the 
ability to not only directly visualise the prostate, but also the adjacent rectum and 
bladder.  The natural extension of volumetric IGRT is the monitoring and potentially 
adaptation of treatment plans based on changes to the target and OARs over the 
extended course of EBRT. 
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CT-based IGRT can be divided into four main categories.  The first category, based 
on beam energy, is divided between MV and kV modalities.  The second category, 
based on beam collimation, is divided between fan beam CT (FBCT) and CBCT.  
Therefore, four main types of CT are available for IGRT: 
1. MV FBCT (e.g. Hi-Art TomoTherapy)  
2. MV CBCT (e.g. Siemens Artiste) 
3. kV FBCT (e.g., CT-on-Rails); 
4. kV CBCT (e.g. Varian OBI or Elekta XVI systems) 
 
The integration of kV CBCT into conventional linac is increasingly common.  In the 
typical on-board CT arrangement, the kV source and detector are mounted on the 
linac gantry perpendicular to the MV axis.  The first prototype kV CBCT-integrated 
linac was developed by Jaffray et al. (see Figure 2.4). (145, 146)  Commercially 
available systems are produced by Varian (OBI) and Elekta (XVI).  An alternative 
solution from Siemens (kVision) is designed such that the a-Si flat-panel detector 
rotates underneath the MV source and the kV source extends opposite it.  The kV 
beam is therefore in-line with the MV beam, projecting in the opposite 
direction.(147) 
 
Figure 2.5: The first linear accelerator modified for kV cone beam computed 
tomography (Jaffray et al.(146)). 
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CBCT volumetric data is reconstructed from multiple projections obtained by a flat-
panel detector as the gantry rotates slowly about the patient.  The speed of image 
acquisition is limited by the gantry speed (~1min/rotation).  The extent of the 
imaging arc required depends on the treatment site.  Applications in head-and-neck 
imaging, for instance, use a symmetric cone beam (full-fan) to image the entire 
patient volume-of-interest (VOI) in each projection over a ~180° arc.  Applications 
in the thorax and pelvis typically require a larger field-of-view (FoV).  To effectively 
increase the FoV, the cone beam and detector are offset laterally (half-fan) and a 
longer arc (~360°) is required.  Approximately two projections are obtained per 
degree of rotation. 
 
 
Figure 2.6: Illustration of Varian OBI full-fan and half-fan geometries. 
Clinical applications of kV CBCT 
The chief advantage of linac-integrated CBCT systems is that the patient can be 
imaged in the treatment position, at the time of treatment.  Assessment of the CBCT 
images can be performed in integrated software, allowing comparison of the 
anatomy from the reference planning CT.  The clinical application of CBCT has 
been widely published.(148-151)  There are concerns, though, over the use of CBCT 
for daily treatment localisation due to the increased imaging dose compared with 
planar imaging.(152)  Therefore, the choice of planar or volumetric imaging for 
prostate IGRT varies across institutions. 
 
Full-fan (full bow-tie) Half-fan (half bow-tie) 
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Boda-Heggemann et al.(153) performed a review of kV CBCT-based IGRT which 
highlighted the potential to obtain additional information with volumetric imaging 
which is not easily achieved with planar modalities, such as monitoring the size and 
shape of the tumour volume and OARs.  CBCT is thereby able to facilitate adaptive 
RT and potentially allows hypofractionation of treatment.(153) 
kV CBCT image quality 
The image quality of kV CBCT has been compared with other in-room CT 
modalities, such as MV CBCT, MV FBCT and kV FBCT.  Conventional, 
diagnostic-quality kV FBCT has been assessed as having the highest image quality, 
followed by kV CBCT, MV FBCT then MV CBCT.(154, 155) 
 
The image quality of kV CBCT is inferior to that of kV FBCT for several reasons.  
The principal factor is the non-collimated geometry which results in increased scatter 
reaching the flat-panel detectors.  CBCT images are subject to reduced signal-to-
noise ratio (SNR), artefacts (streaking/cupping), and reduced contrast (especially for 
soft-tissue). The relatively slow speed of gantry rotation also limits the image quality 
of CBCT as image blur is likely from internal and external patient motion. CBCT 
does though, benefit from higher spatial resolution in the SI plane compared with 
FBCT due to the volumetric nature of CBCT acquisition.  The SI resolution of FBCT 
is dependent on slice thickness and pitch.(146) 
 
There are measures which can be taken to improve CBCT image quality, including 
the use of bow-tie filters, adoption of optimised image acquisition presets and 
reconstruction algorithms (156), and appropriate quality assurance(157).  Reducing 
the FoV and minimising the effects of moving rectal gas has also been shown to 
dramatically improve CBCT images.(158)  Improvements in image quality are 
ongoing since intense research and development in the area ensure rapid 
advancements continue.(159-162) 
kV CBCT imaging dose 
The principle of “as low as reasonably achievable” (ALARA) should be adhered to 
when performing IGRT, therefore it is important to understand and consider the 
imaging dose when assessing IGRT solutions.  The dose from volumetric imaging, 
such as kV CBCT, can be substantially higher than from planar imaging.  Issues 
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relating to the management of imaging dose are detailed in the AAPM Task Group 
75 Report.(152)  Image quality is closely related to imaging dose, such that it is 
important to ensure image quality is sufficient for appropriate use while the required 
dose is not excessive. 
 
While the dose due to a single CBCT is small compared to the overall treatment 
dose, the repeated exposures during a course of treatment can amount to a significant 
dose.(163, 164)  An assessment of CBCT doses by Kan et al.(165) found that 
standard-mode of Varian systems resulted in effective doses up to 2-3 times higher 
than from diagnostic FBCTs and had overall poorer image quality.  They estimated 
that a 35-fraction treatment for prostate cancer would result in approximately 1.5 to 
2.0 Gy to OARs.  Such imaging dose is predicted to have a 4.0 % additional risk of 
induced secondary cancer.(165) 
 
The imaging dose varies greatly depending on the IGRT modality used.  Several 
studies have compared the dose from kV CBCT with that from planar MV and kV 
imaging.(163, 166)  Islam et al. found the maximal dose from MV EPID was 7 cGy 
while the dose from kV planar was 0.25 mGy, and CBCT dose was 2.3 cGy.(163)  
Walter et al.(166) found dose from kV imaging (planar or CBCT) was lower than 
from orthogonal-pair MV imaging, even after the addition of a factor for 
radiobiological equivalence.  Planar kV imaging resulted in rectal doses 
approximately 99 % lower than for MV portal images (5 MU/exposure) with a 
significant improvement in image quality.  The rectal dose from a 360° kV CBCT 
was approximately 73 % lower than from MV orthogonal-pairs.  Walter et al. 
declared that the dose from CBCT is reasonable in comparison with traditional 
planar MV dose.(166)  As well as differences in the magnitude of dose, the nature of 
the dose varies.  Dose from CBCT is distributed throughout a larger volume 
compared with orthogonal-pair planar imaging techniques.(163)   
 
Many assessments of CBCT dose have recommended dose-limitation wherever 
possible.(152, 163, 164, 166, 167)  Unfortunately, the limited image quality of 
CBCT, as discussed above, means it can be difficult to make significant dose 
reductions without affecting usefulness.  There are, though, several ways to decrease 
CBCT imaging dose.  One method is to reduce the exposure settings: peak voltage 
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(kVp) and/or milliamperes (mA).  Alternatively, it is possible to decrease the FoV, 
the scan length, or the gantry rotation arc.  Reducing the FoV effectively reduces the 
gantry rotation as a change from half-fan to full-fan will require fewer projections.  
The reduction in scan length has the potential to improve image quality by reducing 
amount of scatter received by detector.  Innovations in hardware and software 
versions have also resulted in dose-reduction.(167, 168)  When considering dose 
from CBCT, it is important to consider whether planar kV imaging is adequate for 
the task since it offers significant dose sparing.(163, 166) 
2.5.2. Improved outcomes from prostate IGRT 
The principle aim of IGRT is to improve the quality of prostate EBRT by correcting 
uncertainties associated with setup error and organ motion (15, 126).  Ideally, IGRT 
should translate into measurable improvements in tumour control and/or toxicity 
reduction.  The perceived value of IGRT has meant there is a distinct lack of 
evidence from RCTs for its use.  This is largely because it is unethical to randomise 
patients between IGRT and non-IGRT since image-guidance has become an 
important tool that clinicians won’t omit from patients’ treatments. 
 
The importance of quality assurance through IGRT cannot be understated.  The 
underlying value of IGRT is ensuring dose is delivered with greater accuracy by 
reducing geometric variability.  A significant aspect of IGRT is the detection of 
changes during a treatment course which may require adaptation of the plan, such as 
gross setup error, organ motion and deformation (including baseline shifts between 
targets and OARs) and weight loss.  Subsequently, delivered dose is more closely 
correlated with the planned distribution and a better understanding of tumour and 
OAR dose-response should be achieved.  In turn, it is expected that IGRT results in 
more predictable treatment outcome.   
 
An idealised estimation of the potential benefits due to improved precision and 
accuracy from image-guided IMRT has been performed by Ghilezan et al.(169).  
Simulation of patient treatments was performed with a 1 cm CTV-PTV margin for 
conventional IMRT on the simulation CT.  Conversely, the simulations of the IGRT 
were performed with no CTV-PTV margin, on the daily CTs.  Resultant doses for 
the bladder and rectum were compared for the two techniques.  Theoretically, IGRT 
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was able to facilitate an average 13 % dose-escalation to the prostate, although the 
effect varied widely between patients (<5 % - 41 %). 
 
Kupelian et al. demonstrated improved clinical outcomes due to the use of daily 
IGRT.(109)  Since previous studies found that rectal distension at CT simulation led 
to inferior tumour control due to geographic miss(51, 52), it was postulated that daily 
IGRT could correct errors due to variable rectal filling.  At 5 years follow-up, no 
difference in outcome was found for patients planned with a distended rectum 
compared with those with a non-distended rectum, indirectly demonstrating daily 
IGRT was able to correct for variations in rectal distension and improve target 
coverage. 
 
Zelefsky et al. provided further evidence for the improved outcomes from IGRT in a  
comparison of prostate patients treated with FMs (between 2008 and 2009) and 
without FMs (between 2006 and 2007).(170)  High-risk patients treated with daily 
IGRT had significant improvement in biochemical tumour control at 3-years.  There 
was also a lower rate of late urinary toxicity associated with the use of IGRT.  Such 
data suggests IGRT translates into improved clinical outcomes.(170) 
 
A similar comparison of patients treated with or without IGRT was performed by 
Kok et al.(171)  The 243 patients treated with IGRT, in 2008, each received 78 Gy, 
while the 311 non-IGRT patients, treated in 2006, each received 74 Gy.  The IGRT 
cohort underwent daily planar kV imaging using FMs.  The non-IGRT cohort was 
imaged with planar MV imaging (daily for the first week, then weekly) with 
alignment to bony anatomy.  The use of daily FM-based IGRT was found to reduce 
the risk of moderate/severe GI toxicity and the duration of moderate/severe late GU 
toxicity, despite the increase in overall treatment dose from 74 to 78 Gy. 
 
There is potential for IGRT to further improve prostate EBRT outcomes by 
facilitating adaptive techniques, as well as extreme hypofractionation and 
stereotactic methods.  The use of IGRT to create patient-specific PTV margins, i.e., 
adaptive radiotherapy, has been shown to allow significant dose-escalation without 
increasing GU or GI toxicity.(172, 173)  Hypofractionated dose schedules(47, 174) 
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and boosts to dominant intraprostatic lesions(175) rely on rigorous IGRT techniques 
to ensure safe dose-delivery.  
  
Margin size reduction and subsequent dosimetric improvements can be facilitated by 
stringent IGRT methods.(95)  It is important to note, however, that the PTV margin 
size still needs to be large enough to incorporate delineation uncertainties, the effect 
of prostate deformation/rotation, and residual errors (such as intrafraction motion 
and couch-correction errors).  Inappropriate margin reduction can have detrimental 
effects when uncertainties are underestimated.(176-178) 
2.6. Methodological considerations 
The primary aim of this thesis is to compare two IGRT methods, with and without 
FMs, i.e., the use of intraprostatic FMs compared with soft-tissue-based IGRT, using 
CBCT.  The secondary research aims are to assess the interobserver variability of 
RTs aligning FMs on planar kV imaging and to assess the interobserver variability of 
RTs aligning soft-tissues on kV CBCT. 
 
The primary question is explored in “Chapter 4 - Assessment of cone beam CT 
registration for prostate radiation therapy: fiducial marker and soft-tissue methods”.  
The secondary questions are explored in both “Chapter 3 - Interobserver variability 
of radiation therapists aligning to fiducial markers for prostate radiation therapy” 
and “Chapter 4 - Assessment of cone beam CT registration for prostate radiation 
therapy: fiducial marker and soft-tissue methods”. 
2.6.1. Primary research question: Comparison of FMs and soft-tissue (kV 
CBCT) 
2.6.1.1. Literature review: method comparison 
The primary aim of this thesis is to compare the localisation performance from FMs 
and soft-tissue, both using CBCT.  At the time of initiating this thesis, there were 
only two published comparisons of these IGRT methods using kV CBCT(13, 179) 
and one using MV CBCT(180), but several publications have been produced while 
this project has been underway(181-184). 
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Moseley et al. compared soft-tissue alignment using kV CBCT with alignment to 
FMs on CBCT and planar MV imaging.(13)   Moseley et al. concluded that 
interobserver variability was the dominant source of uncertainty in soft-tissue 
alignment compared with FM-based localisation.  On the assumption that MV FMs 
provide a ground-truth of prostate position, it was found that soft-tissue localisation 
of the prostate using kV CBCT (without FMs) has a very small systematic error; 
0.95, 0.35 and 0.99 (mm) in the SI, LR, and AP directions, respectively(13).  It was 
also suggested that CT-guidance provides additional information which is important 
in assessing changes in target and OAR volumes.  Volumetric imaging was also 
indicated as a prerequisite for performing adaptive techniques. 
 
Within an investigation of residual errors from online CBCT-guided prostate EBRT, 
Létourneau et al. performed a comparison of soft-tissue and marker-based 
localisation. (179)  A relatively small sample size (8 patients, 1 image per patient) 
was used to measure localisation differences from Visicoil markers (planar kV) and 
soft-tissue alignment (kV CBCT).(179)  Localisation was based on contours 
delineated by a radiation oncologist in the Pinnacle3 treatment planning system 
rather than using online IGRT tools.  Agreement between the FMs and soft-tissue 
was most evident in the LR plane, while significant differences were found in the SI 
plane (see Table 2.3).  The authors stated that the easy delineation of the lateral 
edges of the prostate assisted accurate LR localisation, while AP alignment was 
complicated by poor differentiation of the prostate edges adjacent to the bladder.  
The poor agreement in the SI planes was attributed to difficulty in distinguishing the 
base and apex of the prostate on both CT scans and volume-averaging from the 
reference FBCT.  The authors claimed accuracy of soft-tissue matching was affected 
by poor CBCT image quality subsequent to blur caused by motion during the long 
acquisition time.   
 
Langen et al. used MV FBCT from a Tomotherapy unit to compare alignment 
methods for prostate IGRT.(180)  Online treatment was based on manual alignment 
to FMs, while offline alignment was performed based on manual alignment of soft-
tissue anatomy, ignoring the FMs.  Alignment using the reference contours was also 
conducted.  Registrations were performed by RTs and by a Radiation Oncologist.  
Registrations were compared with a reference position obtained by extracting the 
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FMs and determining their centre-of-mass (CoM). The fiducial-based registrations 
had the best “agreement” with the reference position, while the contour-based 
alignments agreed the least. It is not surprising that the findings favoured the FM 
match since the reference was itself based on the CoM of the three FMs.  Contour-
based registration differed from the FMs CoM by ≥3 mm for 52 %, 24 %, and 48 %, 
alignments in the SI, LR and AP directions, respectively.  This was improved by the 
use of anatomy-based registration, with differences ≥ 3 mm for 32 % (SI), 3 % (LR), 
and 15 % (AP).  It is possible that the presence of the FMs had a significant impact 
on improving the anatomy-based alignment compared with the contour method.  It is 
reasonable to expect similar or improved soft-tissue localisation with kV CBCT in 
the present study than found by Langen et al. since other comparisons have 
demonstrated similar or worse registration for MV FBCT.(155) 
 
Another comparison of IGRT modalities was performed by Barney et al.(182), who 
compared alignment to FMs on planar kV imaging with alignment to soft-tissue on 
CBCT. The size and type of FMs used in the study was not described.  In the 
comparisons of 286 localisations to FMs and soft-tissue found, 28 % differed by 
>5.0 mm in at least one direction, which was defined as the threshold for clinical 
acceptability.  Barney et al. recognised that the ideal IGRT solution will vary for 
individual patients and suggested that patients unable to undergo insertion of FMs, 
for example due to anticoagulant dependence, would benefit from CBCT-guidance.  
Otherwise, patients with FMs may benefit from the reduced imaging dose associated 
with planar imaging.  Overall, Barney et al. suggest prostate CBCT image quality is 
insufficient to allow for consistent, reproducible identification of the borders of the 
prostate.  The author’s clinic required Radiation Oncologists to perform alignment of 
CBCT, which is a very different practice compared with our clinic (and many other 
Australian sites) where on-line responsibility is largely delegated to RTs. This 
dependence on Radiation Oncologists was an important factor in the decision to use 
planar imaging with FMs rather than soft-tissue alignment with CBCT. 
 
In another comparison of IGRT techniques, Shi et al.(183) found that manual 
alignment to FMs on CBCT was a more accurate method of IGRT compared with 
automatic grey-value alignment of soft-tissue anatomy.  Using the XVI software 
from an Elekta Synergy S linac, (Elekta, Stockholm, Sweden), six patients 
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underwent IGRT using three Visicoil gold markers (0.75 x 10.0 mm, IBA, Santa 
Barbara, CA, USA).  Another six patients had IGRT without the use of FMs.  Shi et 
al. used a one-sample t-test used to assess the alignment discrepancy between IGRT 
methods (p < 0.05 was considered significant). Similar to other studies, a 5 mm 
threshold was established to determine clinical acceptability.  The assessment did not 
utilise Bland-Altman analysis, but since the mean difference and SD were quoted in 
the results, the 95 % LoA can be derived (see Table 2.3).  The authors found that the 
XVI automatic grey-value alignment method differed significantly from the manual 
FM position.  In fact, the automatic grey-value (soft-tissue) alignment had high 
agreement with the bony anatomy alignment since clip boxes used for alignment 
contained bony anatomy that heavily influenced the automatic registration.  Shi et al. 
found soft-tissue alignment was complicated by low radiographic contrast between 
the prostate and adjacent anatomy due to similar CT numbers for prostate, muscles, 
rectum, and bladder wall.  In the case of obese patients, Shi et al. suggest that FMs 
are the only reliable method for prostate localisation since the CBCT image quality 
is further degraded by their large body habitus. 
  
Owen et al. compared planar and volumetric imaging for the detection of FMs.(181)  
The study compared CT-on-rails with MV EPID, finding that differences between 
the isocentres introduced significant errors.  The study also separately compared kV 
CBCT with planar kV imaging.  Patients in the CBCT investigation were localised 
with planar kV imaging to FMs and then CBCT images were acquired after couch 
correction based on a 0 mm action threshold.  CBCTs were subsequently compared 
with MV EPIs taken during treatment (with the same couch position as CBCT) and 
repeat kV planar imaging taken after completion of treatment.  It was estimated that 
approximately 5 mins elapsed between CBCT and EPID acquisition.  The time from 
CBCT to post-treatment kV images was approximately 10 minutes.  This compared 
with an estimation of 2 minutes between images in the study by Moseley et al.(13)  
The kV planar imaging was found to have greater disagreement with FM-localisation 
on CBCT than the MV EPID imaging.  This was likely due to the extra time between 
images, resulting in additional intrafraction motion.  Owen et al. attributed some of 
the differences in FM localisation to differences in volumetric and planar image 
interpretation.(181) 
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Logadóttir et al.(185) compared the use of three imaging modalities: kV planar 
imaging from BrainLAB ExacTrac and OBI; as well as volumetric imaging from the 
OBI CBCT.  All the images were acquired after daily treatment, while initial setup 
was performed with ExacTrac.  The planar imaging relied on three implanted FMs, 
while the CBCT utilised soft-tissue alignment (a combination of automated and 
manual alignment).  Since the initial setup was to FMs on ExacTrac, the results are 
potentially biased towards this system as the “ground truth”.  There was also the 
potential for prostate motion during the treatment session, and between image 
acquisitions.  Therefore, the results are at risk of bias based on the order of image 
acquisition – this was minimised by varying the imaging order during the study.  
Agreement between soft-tissue and FMs was best in the LR direction.  Due to the 
uncertainties in soft-tissue alignment compared with use of FMs, the authors 
recommended use of larger margins for soft-tissue localisation. 
 
Fonteyne et al. assessed a variety of different sized FMs in comparison with CBCT 
soft-tissue guidance.(186)  Automatic fusion based on soft-tissue was found to have 
poor agreement with the FM position.  The accuracy of automatic fusion improved 
as the size of FMs increased, but larger FMs caused increased scatter and image 
artefacts, complicating soft-tissue alignment.  Manual adjustment of the automatic 
registration improved agreement with the FMs, and Fonteyne et al. maintain that 
operator evaluation (for example by RTs) is “imperative”.  
 
Mayyas et al.(184) compared several IGRT modalities (three-dimensional 
ultrasound, kV planar imaging, kV CBCT, and electromagnetic transponders) within 
the same patient group for the purpose of prostate IGRT.  The description of the 
study did not explicitly define whether the planar kV images were localised using a 
bony match or instead used the FMs/Calypso markers.  The comparison of planar kV 
imaging and CBCT was analysed using Pearson correlation coefficient, and found 
high correlation in the LR and AP planes, but low correlation in the SI direction.  It 
should be noted that the correlation coefficient for the SI direction was quoted as two 
different values with the paper: 0.50 in Table II, and 0.65 in Figure 4(b).  The 
authors suggested the low correlation in the SI plane may be due to poor CBCT 
image quality limiting the observer’s ability to define the prostatic base and apex.  
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The temporal difference between images was also considered a potential source of 
differences.  
 
Table 2.3: Summary of studies comparing FMs and soft-tissue prostate alignment 
Study Pt Img Comparison Results 
Létourneau 
2005 (179) 8 8 
kV CBCT: soft-
tissue v. Visicoil 
FMs (0.35 x 40 
mm) 
[Elekta XVI] 
Mean differences (mm):  -1.1 SI;  0.6 LR;  1.0 AP 
SD(mm):  2.9 SI;  0.8 LR;  1.5 AP 
*Calculation of Bland-Altman 95 % LoA 
 (mean diff ± 1.96 SD) 
SI:  -6.8 to 4.6mm 
LR: -1.0 to 2.2 mm 
AP: -1.9 to 3.9 mm 
Moseley 
2007 (13) 15 241 
kV CBCT:  soft-
tissue v. FMs (0.8 x 
3 mm) 
[Elekta XVI] 
Pearson correlation coefficient: 
0.41 SI; 0.90 LR; 0.55 AP 
Bland-Altman 95 % LoA: 
SI: -3.74 to 7.30 mm 
LR: -2.15 to 1.63 mm 
AP: -4.56 to 6.31 mm 
within 3 mm: 64.1 % SI; 90.8 % LR; 63.7 % AP 
Barney 
2011 (182) 36 286 
kV CBCT soft-
tissue v. planar kV 
FMs (0.8 x 3 mm) 
*ST and FMs from 
different images 
[Varian OBI] 
Mean differences (mm): 3.1 SI; 1.3 LR; 3.4 AP 
SD(mm): 2.7 SI; 1.6 LR; 2.6 AP 
Bland-Altman 95 % LoA: 
SI: -9.0 to 5.3 mm 
LR: -4.1 to 3.9 mm 
AP: -4.0 to 9.3 mm 
within 5 mm: 72.7 % SI; 97.2 % LR; 72.4 % AP 
Shi 
2011 (183) 6 252 
kV CBCT: auto 
grey-value v. 
manual FMs 
(Visicoil 0.75 x 10 
mm) 
[Elekta XVI] 
Difference between grey-value and FMs: 
Mean (mm): -5.5 SI; 0.2 LR; -3.1AP 
SD (mm): 4.8 SI; 1.3 LR; 4.3 AP 
*Calculation of Bland-Altman 95 % LoA 
(mean diff ± 1.96 SD) 
SI: -14.9 to 3.9 mm 
LR: -2.3 to 2.7 mm 
AP: -11.5 to 5.3 mm 
Fonteyne 
2012 (186) 22 819 
kV CBCT: auto 
grey-value v. 
manual soft-tissue 
[Elekta XVI] 
Pearson correlation coefficient: 
0.28 SI; 0.33 LR; 0.05 AP (fair to poor) 
Bland-Altman 95 % LoA: 
SI: -11.8 to 6.2 mm 
LR: -12.4 to 10.7 mm 
AP: -15.0 to 12.1 mm 
within 2 mm: 51 % SI; 86 % LR; 38 % AP 
Mayyas 
2013 (184) 27 1100 
kV CBCT soft-
tissue v. planar kV 
[Varian OBI] 
Pearson correlation coefficient: 
0.50 - 0.65 SI; 0.90 LR; 0.80 AP 
AP, anterior-posterior; CBCT, cone beam CT; FMs, fiducial markers; Img, Images; kV, kilovoltage; 
LoA, limits of agreement; LR, left-right; OBI, on-board imager; Pt, Patients; SD, standard deviation; 
SI, superior-inferior; ST, soft-tissue; XVI, x-ray volumetric imaging 
 
2.6.1.2. Methodological considerations: method comparison 
The above comparisons of IGRT methods pose several methodological 
considerations for the present study.  The first consideration is the choice of images 
to compare.  The study by Moseley et al. was designed to compare FMs and soft-
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tissue planar MV and kV CBCT.  It was recognised that it is important to compare 
the localisation of both FMs and soft-tissue match on CBCT in order to reduce 
several sources of error.  By using the CBCT data, there were no differences in 
patient or equipment position which may have led to residual mismatch.  
Conversely, Barney et al. compared soft-tissue CBCT alignment with the FMs on 
planar imaging.(182)  This method potentially includes error from intrafraction 
motion in the time between acquisition of the two images (estimated by Moseley et 
al. as 2 minutes(13)).  Therefore in order to reduce such uncertainties, the present 
study will compare the position of FMs and soft-tissue, both obtained from the same 
CBCT images. 
 
The potential for intrafraction motion between images can be extrapolated from the 
comparison of MV FMs and CBCT FMs by Moseley et al. (13)  Despite the use of 
FMs on both images, differences >3 mm occurred in 8.7 %, 0.3 %, and 4.5 % cases 
in the SI, LR, and AP directions, respectively.  The 95 % LoA for MVFM v 
CBCTFM were -3.85 to 1.86, -0.22 to 2.50 and -3.57 to 2.43 mm in the SI, LR, and 
AP planes respectively).(13)  The biggest differences in FM localisation correlated 
with the planes most likely to have prostate motion.  Some of this difference may 
also be due to slight isocentre differences between the kV CBCT and MV EPID 
systems.   
 
It is also important to acknowledge that the use of FMs with CBCT does incorporate 
its own uncertainty.  Clinically, our institution utilises FMs with planar imaging.  An 
advantage of matching FMs with planar imaging is that all three markers can be 
viewed simultaneously, in all planes.  Therefore when all three markers do not align 
perfectly, any compromise required to “best-fit” the markers is relatively easy.  In 
designing this study, it is expected that it is more complicated to perform FM 
matching with volumetric imaging, since the observer must scroll between slices to 
assess each FM and determine the best-fit of the three markers.  Therefore, the 
interobserver comparisons incorporate FM localisation on both planar and 
volumetric imaging to better understand this effect. 
 
One of the features of the investigation by Moseley et al.(13) was the removal of the 
FMs from CBCT projection data.  This was performed to remove any bias which 
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may have resulted from visualising the FMs when performing soft-tissue alignment.  
Removal of the FMs was also done to reduce the artefacts in the reconstructed CBCT 
which were likely to obscure the prostate boundaries.  A similar process was 
unavailable for the CBCTs used within this thesis. 
 
Both Moseley(13) and Langen(180) conceded that assessing soft-tissue alignment 
against FMs may not be ideal, since the FMs are a surrogate for prostate motion and 
may not adequately reflect prostate changes during the course of treatment.  It could 
be argued, then, that some of the differences between soft-tissue and FM alignment 
found by this investigation may be due to the limited ability of FMs to act as a 
prostate surrogate.  Since prostate deformation is generally small and because there 
are few, if any, viable alternatives, it is reasonable to consider FMs as the ground-
truth for prostate position.   
2.6.1.3. Statistical considerations: method comparison 
The studies outlined above have primarily used two statistical methods to quantify 
the agreement between different methods of prostate IGRT: Pearson Correlation 
Coefficients; and Bland-Altman analysis of agreement.  While correlation 
coefficients have been widely used to compare methods of measurement in IGRT 
studies., it has been shown that determining correlation is an inappropriate 
assessment since it measures linear association rather than agreement.(20, 187)  Two 
IGRT methods may be highly correlated, but differ greatly, as shown in Figure 2.6.  
In this example, the measured data would have a perfect correlation of 1.00, but have 
a mean difference of 2.0 mm. 
 
 
Figure 2.7: Example measurements 
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Bland and Altman have shown that it is inappropriate to simply compare means, or 
use correlation or regression in order to establish the level of agreement between 
methods of measurement.(20)  They proposed an alternative statistical technique, 
which now bears their name, for the comparison of measurement methods.(20, 187)  
The Bland-Altman analysis was originally described in terms of comparing 
measurements for systolic blood pressure, and has since been widely applied to 
evaluation of intra- and interobserver agreement for continuous variables. 
 
The purpose of comparing an established standard measurement (e.g. FMs) against a 
new method (e.g. soft-tissue) is to determine whether the new method provides 
results which are similar enough to the established method that the techniques can be 
considered interchangeable.  Ultimately, the comparison of the two methods can be 
as much a clinical evaluation as a statistical one.  It is important to consider whether 
the differences found are likely to have a clinically significant impact.  While two 
methods will have a degree of measurement difference, other factors can influence 
the suitability of the new method, such as reduced cost, improved patient 
satisfaction, imaging dose, training requirements, and additional workload. 
 
The Bland-Altman technique is used to calculate the mean difference between 
observations, the standard deviation of the differences and estimate the 95 % limits 
of agreement (LoA): 95 % LoA = mean of the differences ± 1.96 X SD of the 
differences.  The 95 % LoA estimate the range that measurements can be expected to 
agree within, for most subjects.  An appropriate sample size of 100 to 200 
measurements is important in Bland-Altman assessment otherwise it can incorrectly 
find agreement between the methods.(188) 
 
A visual assessment of Bland-Altman scatter-plot (mean versus the difference of 
observations) is important to assess whether there is any relationship between 
observation differences with the level of measurement.  For instance, measurement 
of large displacements may have greater differences between methods than 
measurement of small displacement.  
 
 Chapter 2:  Background and literature review 46 
 
Like Moseley et al.(13), Barney et al.(182) used the Bland-Altman limits of 
agreement (LoA) method to assess the agreement between FMs and soft-tissue 
alignment.  There is some inconsistency in the results from Barney et al., as the 
quoted 95 % LoA (-9.0 to 5.3 mm SI; -4.1 to 3.9 mm LR; and -4.0 to 9.3 mm AP) do 
not equate with the published mean difference (3.1 mm SI; 1.3 mm LR; 3.4 mm AP) 
and SD (2.7 mm SI; 1.6 mm LR; 2.6 mm AP).  Either the LoA are calculated 
incorrectly or the mean difference and SD are quoted in reverse.  For example, 
calculation using the quoted mean difference and SD for the SI plane results in 95 % 
LoA of -3.1 ± (1.96 x 2.7) = -8.4 to 2.2 mm.  The recalculation results from Barney 
et al. are listed in Table 2.4. 
 
Table 2.4: Recalculation of 95 % LoA from Barney et al. 
Plane Mean Difference SD Published 95 % LoA Recalculated 95 % LoA 
SI 3.1 2.7 -9.0 to 5.3 -8.4 to 2.2 
LR 1.3 1.6 -4.1 to 3.9 -4.4 to 1.8 
AP 3.4 2.6 -4.0 to 9.3 -1.7 to 8.5 
 
2.6.2. Secondary research questions: Assessment of interobserver variability 
2.6.2.1. Literature review: planar FM interobserver variability 
Ideally, IGRT should achieve consistent, accurate localisation without significant 
differences between various operators, i.e. it should have good interobserver 
agreement.  Interobserver variability is an important factor in understanding IGRT 
accuracy.  Any variations between observers can introduce systematic and random 
errors into the IGRT process.  Like other uncertainties, interobserver variability can 
shift and/or blur the delivered dose with respect to the target.  Large differences in 
isocentre alignment between observers can have a significant impact on treatment 
accuracy.  Since margin design should incorporate all uncertainties, it is important to 
evaluate and understand IGRT interobserver variability.   
 
Studies assessing interobserver variability using planar imaging date back to side-by-
side reviews of simulator film against either portal films (189) or EPID images 
(190).  Both studies demonstrated significant subjectivity between observers.  Bissett 
et al. expressed surprise at the extent of interobserver variability and stated 
“acceptable reliability in radiotherapy portal verification will only be achieved when 
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subjective decision making is eliminated” (190).  Much of the variability found in 
these studies is likely to be due to limitations in the side-by-side nature of the image 
review.  Image review techniques have improved since these studies.  Electronic 
imaging has allowed use of software tools which allow manipulation of the image to 
enhance anatomical features. It is now possible to overlay the reference and 
treatment image.  Many systems allow stereoscopic review rather than by individual 
projection.   
 
As the use of electronic portal imaging became more widespread, the opportunity to 
delegate image review from the ROs to RTs arose.(191) To assess the transfer of 
responsibility, a number of interobserver studies comparing localisation by RTs and 
ROs were conducted.(192, 193)  Suter et al. concluded that localisation by RTs 
agreed with ROs such that the RTs became responsible for image verification in their 
department.(192)  Lewis et al. also found that, with appropriate training, RTs were 
able to consistently localise pelvic bony anatomy using MV EPID.(194) 
 
Prostate-specific studies have followed these more generic interobserver variability 
investigations.  A number of studies have been conducted assessing interobserver 
variability for alignment to either bony anatomy (195, 196) or FMs (13, 196, 197) 
using MV EPID.  Estimates of interobserver variability from these studies are 
summarised in Table 2.5.   
 
Berthelet et al. found that trained RTs were able to consistently align to bony 
anatomy on MV EPID for prostate EBRT.(195)  No significant interobserver 
differences were found when registering anterior and lateral MV images.  
Interobserver variability was least in the LR direction (SD: 0.7 mm), and most 
evident in the SI plane (SD: 1.7 mm).(195)   
 
More recent assessments of prostate IGRT interobserver variability have 
concentrated on FMs with MV EPID.(13, 196, 197)  Moseley et al. found 
interobserver systematic and random errors < 1 mm.(13)  Ullman et al. found 
similarly consistency amongst the RTs in a small study comprising two patients and 
10 image-pairs.(197)  Such a small sample size may not accurately estimate 
interobserver variability since two patients are unlikely to be representative of the 
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greater population.  It is possible the inclusion of more patients may have resulted in 
greater observer variation.  Patient factors, such as the position of FMs, may have 
influenced the ease of FM matching.  
 
Table 2.5:  Summary of prostate EBRT interobserver variability studies using planar 
imaging 
Study Obs Pts Image pairs Surrogate Modality 
Reported interobserver 
variability 
Berthelet 
2006 (195) 6 RTs 20 200 BA 
DRR v. 
MV EPID 
Mean within-image SD: 
Anterior portal image: 
1.0 mm (SI); 0.7 mm (LR) 
Lateral portal image: 
1.4 mm (SI); 1.7 mm (AP) 
Ullman 
2006 (197) 4 RTs 2 10 
4 FMs 
(1.2 x 3 
mm) 
DRR v. 
MV EPID 
Mean = 0.9 mm; 
median = 0.6 mm; 
SD = 0.7 mm 
Moseley 
2007 (13) 5 RTs 5 5 
3 FMs 
(0.8 x 3 
mm) 
DRR v. 
MV EPID 
Group Systematic error (M): 
0.01 mm SI; 0.03 mm LR; 0.15 
mm AP 
Systematic error (Σ): 
0.28 mm SI; 0.09 mm LR; 0.36 
mm AP 
Random error (σ): 
0.47 mm SI; 0.26 mm LR; 0.95 
mm AP 
Kong 
2011 (196) 5 RTs 50 150 BA 
DRR v. 
MV EPID 
ICC: 0.63 
(0.63-0.43 SI; 0.90 LR; 0.55 
AP) 
Kong 
2011 (196) 5 RTs 50 150 
3 FMs 
(1.0 x 3 
mm) 
(CoM) 
DRR v. 
MV EPID 
ICC: 0.95 
(0.94-0.95 SI; 0.96 LR; 0.95 
AP) 
AP, anterior-posterior; BA, bony anatomy; CoM, centre-of-mass; DRR, digitally reconstructed 
radiograph; EPID, electronic portal imaging device; FMs, fiducial markers; LR, left-right; ICC, 
intraclass correlation coefficient; MV, megavoltage; Obs, observers; Pts, Patients; RTs, radiation 
therapists; SI, superior-inferior; Sim, simulator; SD, standard deviation. 
 
Kong et al. examined various methods of alignment to FMs, as well as alignment to 
bony anatomy.  They found excellent interobserver agreement for centre-of-mass 
alignment of intra-prostatic FMs.(196)  The use of FMs was found to reduce 
interobserver variability on MV EPID compared with alignment to bony anatomy.  
The FMs provide discrete, unambiguous points for image localisation and are 
designed to be readily visualised on both DRRS and MV EPID.  In comparison, 
bony anatomy can be difficult to discern on MV images since there is little 
differential attenuation between soft-tissue and bony anatomy at this energy. The use 
of small-field treatment portals for localisation has been shown to increase 
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interobserver variability due to the limited visibility of anatomical structures in the 
FoV.(194) 
2.6.2.2. Literature review: soft-tissue kV CBCT interobserver variability 
Similar to planar imaging for prostate EBRT, the degree of interobserver variability 
found in volumetric imaging has been the topic of numerous studies.  One of the 
earliest evaluations of interobserver variability of prostate localisation with 
volumetric imaging used FBCT.  Court et al. used 28 CTs from two patients to 
assess the variability of seven observers when aligning the prostate using contours 
with and without access to the reference CT.(198)  The contour-based alignment 
method was found to be an accurate method of prostate localisation while the use of 
reference CT data reduced interobserver variability.(198)  Further studies have gone 
on to assess the variability of prostate alignment using CBCT which has reduced 
image quality compared with FBCT. 
 
Morrow et al. assessed prostate localisation using with MV FBCT, MV CBCT, kV 
FBCT, and kV CBCT.(155)  Image quality was found to be directly related to the 
interobserver variability of prostate registration, such that kV FBCT had the highest 
image quality and the greatest consistency, followed by kV CBCT, MV FBCT, and 
finally, MV CBCT.(155)  An assessment of prostate IGRT using MV FBCT by 
Langen et al.(180) found that use of FMs reduced interobserver variability compared 
with soft-tissue alignment.  Since Morrow et al.(155) demonstrated the relatively 
poor image quality of MV FBCT, it is possible that soft-tissue localisation is 
improved on kV CBCT and the difference between FMs and soft-tissue may be 
reduced.  
 
Some evidence for the variability in prostate localisation on CBCT can be inferred 
from studies of prostate delineation.  In the study by White et al. five expert GU 
radiation oncologists had significant interobserver variability when delineating the 
prostate boundaries on CBCT.(199) The mean SD for prostate boundary 
displacements were 3.6, 1.8 and 2.1 mm in the SI, LR and AP planes respectively.  
“Rigorous” education and IGRT protocols were recommended to reduce the 
potential for significant misalignments when using soft-tissue guidance.  Lütgendorf-
Caucig et al. found that interobserver variability of prostate delineation on CBCT 
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was greater than for kV FBCT and MRI.(200)  Contouring differences were 
particularly apparent in the SI direction.  Increased patient diameter was found to 
degrade the CBCT image quality due to increased scatter and ring artefacts.  The 
interobserver variability of prostate delineation increased with the poor CBCT image 
quality.(200)  
 
Jereczek-Fossa et al. assessed the interobserver agreement for alignment of the soft-
tissue prostate on kV CBCT, without the use of FMs.(201)  Interobserver agreement 
was determined by comparing online localisation, performed by a radiation 
oncologist (RO), with the offline localisation performed by another RO and 4 RTs.  
The evaluation used weighted Cohen’s kappa methodology, with scoring according 
to Landis and Koch system (graduated scale light to perfect agreement).  
“Substantial” agreement was found (weighted kappa > 0.6) in ten comparisons and 
“moderate” agreement (0.41-0.60) in the remaining six cases.  Overall, it was 
determined that RTs were able to localise the prostate comparably with ROs 
 
Table 2.6:  Summary of prostate EBRT interobserver variability studies using kV 
CBCT 
Study Obs Pt Img Surrogate Reported interobserver variability 
Moseley 
2007(13) 5 RTs 5 5 
CTV 
contour 
Group Systematic error (mm): 1.28 SI;  
-1.37 LR; -0.40 AP 
Systematic error (Σ) (mm): 2.21 SI; 0.61 
LR; 1.61 AP 
Random error (σ) (mm): 2.85 SI; 1.50 LR; 
2.86 AP 
Morrow, 
2012(155)  1 1  SD(mm): 2.5 SI; 1.3 LR; 0.6 AP 
Jereczek-
Fossa, 
2013(201) 
2 ROs 
(1 online, 
1 offline) 
4 RTs 
6 152 ST 
Differences between online and 4 offline 
observers (mm): 
Mean: 0.9 SI; 1.9 LR; -0.7 AP 
SD: 3.6 SI; 2.7 LR; 3.6 AP 
Img, images; Obs, observers; Pt, patients; ROs, radiation oncologists; RTs, radiation therapists 
 
Moseley et al. assessed the interobserver variability of alignment to soft-tissue using 
kV CBCT.(13)  Five RTs performed image registration on an image set from each of 
five patients.  The RTs had prior experience with image-registration in the context of 
treatment planning, and were otherwise involved in the local IGRT program.  Image 
registration was performed using the CTV contour, and access to the reference CT 
was not permitted.  The resultant interobserver variability was higher than for 
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alignment to FMs on planar MV imaging.  In fact, the authors considered 
interobserver variability was the dominant source of error in soft-tissue alignment 
with CBCT.(13) 
2.6.2.3. Methodological considerations: Interobserver variability 
Each of the planar imaging interobserver variability studies utilised MV imaging and 
performed independent analysis of the anterior and lateral images.  It is possible that 
interobserver agreement is improved with the use of kV imaging and stereoscopic 
image review – as is the practice at ROMC.  Kong et al. suggested that the amount 
of  interobserver variability is influenced by factors which affect the ability to 
identify the FMs, such as variable marker length(196), supporting the motivation to 
determine interobserver variability using local practices.  
 
There is evidence that localisation of FMs with kV imaging can differ from results 
using MV imaging.  Gill et al. compared the historical data obtained from MV and 
kV images and differences between the distribution of displacements measured.(202)  
Since the kV unit had remote couch corrections, no threshold for couch correction 
was applied.  All measured shifts were automatically applied prior to treatment.  
Since the MV unit required manual adjustment of the couch, a threshold of 3.0mm 
applied for isocentre corrections.  Gill et al. argued that the MV image quality and 
lack of remote couch affected observer decisions.(202)  It was postulated that the 
RTs were more likely to measure displacements just under the threshold rather than 
just over, perhaps because the FMs were difficult to align on MV imaging. 
 
Another factor not included in the interobserver studies is the effect of performing 
IGRT in the busy online environment. None of the above studies compared the 
actual online localisation with repeat localisations performed offline.  It is possible 
that the online corrections have greater variability compared with the offline 
measurement included in the studies since there is considerable pressure on the 
treating RTs to perform online IGRT in a timely manner.  Therefore, this 
investigation includes comparisons of online and offline evaluation of planar 
imaging. 
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2.6.2.4. Statistical considerations: Interobserver variability 
Use of any IGRT method to align the prostate only provides an estimation of the 
actual prostate position.  The estimation of position may vary with repeated 
measurements by either the same or other observers.  Understanding the degree of 
variation between multiple observers, the ‘interobserver variability”, gives a greater 
understanding of the precision of the localisation performance of the IGRT method. 
 
The studies mentioned above have used a variety of statistical measures to estimate 
interobserver variability, as outlined in Table 3.3.  Berthelet et al. reported the mean 
within-image SD for each of the anterior and lateral portal images (195).  Ullmann et 
al. described the mean, median and SD of the alignments (197).  Kong et al. 
calculated the overall intraclass correlation coefficient (ICC) for each alignment 
method as well as the ICC for each plane (196).  As outlined in the statistical 
considerations for comparison of IGRT methods (Section 2.6.1.3), the comparison of 
means or the use of correlation and regression is less than ideal for determining the 
agreement of measurements.   
 
Interobserver variability is consistent with Barnhart et al.’s definition of 
“reproducibility” being the “closeness between observations made under conditions 
other than pure replication, e.g. by different observers.”(203)  Therefore, the use of 
Bland-Altman analysis (as described in Section 2.6.1.3) is more appropriate when 
determining the closeness of multiple observers.  In simplest use, Bland-Altman 
analysis can be used to compare observers in a pairwise fashion.  Such comparisons 
can become cumbersome since they require multiple calculations and plots (three for 
three observers, six for four observers, etc.).  Jones et al. proposed a modification to 
the Bland-Altman LoA technique, whereby multiple observers can be compared 
simultaneously.(204)  In the Jones technique, each observer is compared with the 
mean of all the observers which is consistent with the definition of agreement from 
Barnhart et al. as “assessing precision around the mean of the readings”.(203) 
2.7. Patient Characteristics 
In the assessment of interobserver variability of RTs aligning FMs on planar kV 
imaging, Chapter 3, daily imaging from six patients has been included.  The detail of 
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this cohort is outlined in Table 2.7.  The assessment includes the observations made 
in the online environment and by three offline observers  
 
Table 2.7: Patient Cohort 1 (Chapter 3) 
Pt TNM Gleason score Age* Dose (fractions) Images analysed 
1 T3aN0M0 4+4 68.5 74 Gy (37) 36 
2 T3aN0M0 5+4 64.4 78 Gy (39) 37 
3 T4N0M0 4+5 84.8 78 Gy (39) 39 
4 T2aN0M0 3+4 67.7 74 Gy (37) 37 
5 T2bN0M0 4+5 57.7 78 Gy (39) 39 
6 T2bN0M0 NR 72.6 74 Gy (37) 37 
Median age: 68.1 Total: 228 fractions 225 
*age at first fraction; NR, not recorded. 
 
A  separate cohort of six patients was included in the comparison of FMs and soft-
tissue guidance and the assessment of CBCT interobserver variability (Chapter 4).  
Details of these six patients are outlined in Table 2.8.  Three RTs performed CBCT-
based registration to FMs and soft-tissue in this investigation. 
 
Table 2.8: Patient Cohort 2 (Chapter 4) 
 
2.8. Chapter Summary 
Prostate EBRT has undergone significant improvements over recent decades.  The 
accuracy of treatment localisation has become increasingly important as we seek to 
deliver higher tumour dose without increasing treatment-related toxicity.  In clinical 
practice, numerous uncertainties must be accounted for, particularly motion of the 
prostate.  IGRT is an important tool in managing such uncertainties.  There are 
multiple IGRT modalities available in the clinic and it is not immediately clear 
which is the most appropriate. 
 
Pt TNM Gleason score Age* Dose (fractions) Images analysed 
7 T2aN0M0 3+3 74.7 74 Gy (37) 31 
9 T1cN0M0 3+4 64.1 74 Gy (37) 30 
11 T2bN0M0 4+3 70.8 74 Gy (37) 29 
13 T2N0M0 4+5 73.9 76 Gy (38) 33 
23 T1cN0M0 NR 68.4 78 Gy (39) 29 
24 T2aN0M0 4+3 61.2 78 Gy (39) 33 
Median age: 68.1 Total: 227 fractions 185 
*age at first fraction; NR, not recorded. 
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The literature has demonstrated that FMs are a good surrogate for prostate position.  
They serve to identify prostate position at the time of treatment using low-dose 
imaging techniques.  The use of FMs does have inherent risks, though, and not all 
patients are able to benefit from their use.  While the cost-effectiveness of FMs has 
been demonstrated, they do result in additional costs to the patient and/or clinic.  
Alternatively, studies have shown that soft-tissue-based prostate localisation may be 
a viable alternative to FM-based IGRT.  Direct visualisation of the prostate on 
volumetric imaging has the potential to reduce the dependence on surrogates such as 
FMs. 
 
This investigation is designed to clarify the role of CBCT for prostate localisation by 
quantifying the degree of interobserver variability inherent in planar and volumetric 
IGRT.  It will also quantify the difference in localisation found between each 
modality.  As a result, this investigation will inform the evidence-based use of IGRT 
for prostate EBRT.  Chapter 3 will examine the consistency with which RTs align 
FMs on planar kV imaging.  Chapter 4 investigates the degree of interobserver 
variability for registration of FMs and soft-tissue using CBCT. Chapter 4 also 
examines the agreement between FM registration and soft-tissue alignment using 
CBCT. 
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3.2. Abstract: 
3.2.1. Introduction 
As the use of fiducial markers (FMs) for the localisation of the prostate during 
external beam radiation therapy (EBRT) has become part of routine practice, 
Radiation Therapists (RTs) have become increasingly responsible for online image 
interpretation.  The aim of this investigation was to quantify the level of agreement 
between RTs when localising to FMs with orthogonal kilovoltage (kV) imaging.  
3.2.2. Methods 
Six patients receiving prostate EBRT utilising FMs were included in this study.  
Treatment localisation was performed using kV imaging prior to each fraction.  
Online stereoscopic assessment of FMs, performed by the treating RTs, was 
compared with the offline assessment by three RTs.  Observer agreement was 
determined by pairwise Bland-Altman analysis. 
3.2.3. Results 
Stereoscopic analysis of 225 image pairs was performed online at the time of 
treatment, and offline by three RT observers.  Eighteen pairwise Bland-Altman 
analyses were completed to assess the level of agreement between observers.  
Localisation by RTs was found to be within clinically acceptable 95 % limits of 
agreement (LoA).   
3.2.4. Conclusions 
Small differences between RTs, in both the online and offline setting, were found to 
be within clinically acceptable limits.  RTs were able to make consistent and reliable 
judgements when matching FMs on planar kV imaging.  
3.2.5. Key Words 
Fiducial Marker; Observer variability; Radiation Therapy 
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3.3. Introduction 
The successful delivery of conformal and intensity modulated external beam 
radiation therapy (EBRT) relies on the ability to consistently localise the planned 
target volume.  Combining precise dosimetry and accurate treatment delivery is vital 
since there is a risk that factors such as organ motion will result in under dosage of 
the tumour due to geographical miss or overdose of organs at risk, such as the rectum 
(205).  Due to the high likelihood of prostate organ motion relative to bony anatomy 
(8, 9, 51, 206), various localisation strategies have been adopted to correct for 
prostate displacement.  Fiducial markers (FMs) are often implanted into the prostate 
as a surrogate of prostate position on radiographic images.  They allow the position 
of the prostate within the pelvis to be determined at each radiation therapy treatment 
fraction, independent of bony anatomy, so that interfraction positioning uncertainty 
can be reduced (129).   
 
Localisation with FMs has led to an increased imaging workload and, subsequently, 
more frequent online image registration by the treating radiation therapists (RTs).  
As a result, an evaluation of the consistency amongst RTs evaluating FM 
displacement was undertaken.  Other publications have examined the interobserver 
variability of RTs localising to FMs (195-197).  These studies have examined 
localisation based on megavoltage (MV) portal imaging, whereas, our clinic 
exclusively uses orthogonal kilovoltage (kV) images for localisation with FMs. 
 
The purpose of this study was to determine the consistency of RTs aligning to FMs 
on kV images.  The study investigated whether treating RTs (online observers) 
match to FMs differently in comparison with offline RTs. 
3.4. Methods 
3.4.1. Patient selection and preparation 
Six patients undergoing radical EBRT for localised prostate cancer between January 
and April 2010 were included in this study.  The study protocol was reviewed and 
approved by the institutional ethics committee and each patient provided informed 
consent.  Treatment was prescribed as either 74 Gy in 37 fractions or 78 Gy in 39 
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fractions.  Three gold FMs (0.9 x 3.0 mm, CIVCO, Kalona, IA, USA) were inserted 
under trans-rectal ultrasound guidance into the patient’s prostate at least seven days 
prior to simulation by the treating urologist or radiologist.   
3.4.2. Simulation and reference image generation 
Simulation was performed on a Somatom Sensation Open CT scanner (Siemens AG, 
Erlangen, Germany).  The patients were positioned supine, using a Posifix headrest, 
indexed Knee-Lok and Foot-Lok positioners (all CIVCO) on a flat, carbon-fibre 
couch top.  A non-contrast CT was acquired with a 2.0 mm slice thickness.  The 
reference CT was used to create digitally reconstructed radiograph (DRR) reference 
images.  The AcQSim3 module within the Pinnacle3 (Philips Healthcare, Best, the 
Netherlands) treatment planning system (TPS) was used to ensure visualisation of 
the FMs on each DRR.  A volume of interest (VOI) which excluded anatomy 
overlying the FMs, such as femoral head and necks, was defined for DRR 
generation, see Figure 3.1.  Only anatomy within the defined VOI was included in 
the DRR image.  
 
 
Figure 3.1: Example of anterior and lateral DRRs used for fiducial marker (FM) 
match whereby the field-of-view was defined to enhance FM visualisation by 
excluding overlying bony anatomy (arrows denote FM position). 
 
   
Chapter 3: Interobserver variability of radiation therapists 
aligning to fiducial markers for prostate radiation therapy 
61 
 
3.4.3. Localisation image acquisition 
All patients were treated on a Varian Clinac iX linear accelerator, incorporating an 
On-Board Imager (OBI) kV imaging system (Varian, Palo Alto, CA, USA).  Patients 
were initially aligned using their external skin marks.  Orthogonal kV images 
(anterior and right lateral) were obtained to localise the FMs prior to daily treatment. 
3.4.4. Online image assessment 
Pre-treatment kV images were assessed online using the OBI software prior to each 
treatment.  Assessment was performed by a treating RT and confirmed by another 
treating RT.  The registration process consisted of aligning the FMs on the acquired 
kV images with the overlaid reference DRRs.  Correction for displacement of FMs 
was limited to couch translation in the superior-inferior (SI), left-right (LR) and 
anterior-posterior (AP) directions.  Online localisation to FMs was performed with a 
3.0 mm action level.  If the isocentre was out of tolerance in any one direction, the 
couch shift was performed for all three planes.  These online corrections were 
performed by applying the couch shift remotely.  All online measurements of FM 
displacement were recorded in the MOSAIQ electronic medical record (version 1.60, 
IMPAC Medical Systems, Sunnyvale, CA, USA), regardless of whether they were 
applied.  
3.4.5. Offline image assessment 
Three RTs (Obs1, Obs2 and Obs3) performed offline FM registration using the 
MOSAIQ software.  The offline observers had varied experience: 14, 4 and 6 years 
of experience as RTs, respectively.  Their experience with matching to FMs was less 
than one year.  Stereoscopic image registration was performed utilising curve 
templates drawn around each FM on the reference DRRs. 
3.4.6. Statistical analysis 
Paired comparisons of observers, in the form of Bland-Altman (187) analysis of 
agreement, were performed using Analyse-It® software (Method Evaluation Edition, 
Analyse-It Software Ltd, Leeds, UK).   This analysis was used to determine the bias, 
or mean of the observer differences for the multiple observer pairs.  The 95 % limits 
of agreement (LoA), defined as the mean of the observer differences ± 1.96 times the 
standard deviation (SD) of the differences, were also determined for each observer 
pair.  Clinically acceptable 95 % LoA were defined as ±2.0 mm.  These 95 % LoA 
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were defined to reflect the 3.0 mm action level used in our clinic.  The 95 % 
confidence intervals (CI) for the mean difference and LoA were also calculated.   
3.5. Results 
Six patients underwent prostate EBRT utilising daily FM-based localisation between 
January and April 2010.  Three of the patients received 37 fractions of EBRT while 
the other three patients completed 39 fractions.  A total of 228 fractions were 
delivered.  Two fractions were not included in the analysis since the online match 
was not recorded.  The offline review for one fraction was not possible since the 
lateral kV image was unavailable in the MOSAIQ database.  Therefore, 225 of the 
228 possible treatment fractions were included in the analysis.   
3.5.1. Comparison of online and offline observers 
The pairwise Bland-Altman analysis of online versus offline observer measurements 
is shown in Table 3.1.    Typically, the comparison of online and offline observations 
were within the predefined ±2.0 mm clinically acceptable 95 % LoA.  Interobserver 
agreement was best in the LR direction where the 95 % LoA were estimated to be 
within ±1.5 mm.   For both the SI and AP directions, the 95 % CI of the 95 % LoA 
exceeded 2.0 mm, slightly for Obs2 versus OnL and to a greater extent for Obs3 
versus OnL.  The online and offline observers’ measurements agreed within 2.0mm 
or better for 99.1 % fractions in the SI direction; 100.0 % LR; and 99.3 % AP. 
3.5.2. Comparison of offline observers 
The results of the pairwise Bland-Altman comparison of offline observer 
measurements are shown in Table 3.2.  All pairwise Bland-Altman analysis of the 
offline observers resulted in 95 % LoA within the predefined ±2.0 mm LoA of 
clinical acceptability.  Interobserver variability between the offline observers was 
least evident in the LR direction where agreement was within ±1.5 mm 95 % LoA. 
The offline observers’ measurements agreed within 2.0mm or better for 100.0 % 
fractions in the SI direction; 100.0 % LR; and 99.7 % AP. 
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Table 3.1: Pairwise Bland-Altman analysis of online and offline observers 
 Observers Compared 
Mean of 
Difference 
(mm) 
95 % 
CI 
SD of 
Difference 
Lower 
95 % 
LoA 
95 % CI 
Lower 
LoA 
Upper 
95 % 
LoA 
95 % 
CI 
Upper 
LoA  
SI 
 
OnL Obs1 -0.21 
-0.32 
0.82 -1.82 
-2.00 
1.40 
1.22 
-0.10 -1.63 1.59 
OnL Obs2 -0.12 
-0.24 
0.89 -1.86 
-2.06 
1.62 
1.42 
0.00 -1.66 1.82 
OnL Obs3 -0.26 
-0.38 
0.88 -1.98 
-2.17 
1.45 
1.26 
-0.15 -1.78 1.65 
LR 
OnL Obs1 0.08 
 0.00 
0.61 -1.11 
-1.25 
1.27 
1.13 
 0.16 -0.97 1.41 
OnL Obs2 0.12 
 0.04 
0.61 -1.08 
-1.22 
1.32 
1.18 
 0.20 -0.94 1.46 
OnL Obs3 0.06 
 -0.03 
0.66 -1.23 
-1.37 
1.34 
1.20 
 0.14 -1.08 1.49 
AP 
OnL Obs1 -0.20 
-0.29 
0.72 -1.60 
-1.76 
1.21 
1.05 
-0.10 -1.44 1.37 
OnL Obs2 -0.26 
-0.37 
0.81 -1.85 
-2.04 
1.33 
1.15 
-0.16 -1.67 1.51 
OnL Obs3 -0.35 
-0.47 
0.93 -2.17 
-2.37 
1.47 
1.26 
-0.21 -1.96 1.68 
SI: superior-inferior;  LR:  left-right;  AP:  anterior-posterior;  OnL:  Online;  Obs1: offline observer 1; Obs2:  
offline observer 2; Obs3:  offline observer 3;  CI:  confidence interval;  SD: standard deviation;  LoA:  limit of 
agreement. 
 
Table 3.2: Pairwise Bland-Altman analysis of offline observers 
 
Observers 
Compared 
Mean of 
Difference 
(mm) 
95 % 
CI 
SD of 
Difference 
Lower 95 
% LoA 
95 % 
CI 
Lower 
LoA 
Upper 
95 % 
LoA 
95 % CI 
Upper 
LoA  
SI 
 
Obs1 Obs2 0.09 
 0.00 
0.68 -1.24 
-1.39 
1.41 
1.26 
 0.18 -1.08 1.56 
Obs1 Obs3 -0.05 
-0.14 
0.68 -1.38 
-1.54 
1.28 
1.13 
 0.04 -1.23 1.43 
Obs2 Obs3 -0.14 
-0.24 
0.77 -1.66 
-1.83 
1.37 
1.20 
 -0.04 -1.48 1.54 
LR 
Obs1 Obs2 0.04 
-0.04 
0.58 -1.09 
-1.22 
1.17 
1.04 
 0.12 -0.96 1.30 
Obs1 Obs3 -0.02 
-0.11 
0.64 -1.27 
-1.41 
1.23 
1.08 
 0.06 -1.13 1.37 
Obs2 Obs3 -0.06 
-0.15 
0.64 -1.33 
-1.47 
1.20 
1.06 
 0.02 -1.18 1.35 
AP 
Obs1 Obs2 -0.07 
-0.16 
0.74 -1.51 
-1.68 
1.38 
1.21 
 0.03 -1.35 1.55 
Obs1 Obs3 -0.15 
-0.25 
0.79 -1.69 
-1.87 
1.39 
1.22 
-0.05 -1.52 1.57 
Obs2 Obs3 -0.08 
-0.20 
0.86 -1.77 
-1.96 
1.60 
1.41 
 0.03 -1.58 1.79 
SI: superior-inferior;  LR:  left-right;  AP:  anterior-posterior;  OnL:  Online;  Obs1: offline observer 1; Obs2:  
offline observer 2; Obs3:  offline observer 3;  CI:  confidence interval;  SD: standard deviation;  LoA:  limit of 
agreement. 
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3.6. Discussion 
This study examined whether, when using planar kV imaging, RTs were able to 
align FMs within clinically acceptable limits.  As we have transitioned from bony 
alignment to the use of FMs, it is important to examine the accuracy of image 
guidance methods.  An understanding of interobserver variability is especially 
important to inform comparison of planar and volumetric methods as the use of 
CBCT and soft-tissue alignment increases. The study has demonstrated that RTs are 
able to accurately and consistently align FMs in order to autonomously perform 
daily FM-based image-guided prostate EBRT. 
 
Comparisons of the online and offline observers were typically within the predefined 
clinically acceptable 2.0 mm 95 % LoA.  The mean differences between online and 
offline measurements were very small (<0.4 mm) and demonstrate RTs are able to 
consistently and accurately localise to FMs, whether in the busy online environment 
or offline. 
 
Since this study was performed with a 3.0 mm action level for the online 
observations, it was a concern that online observers may have tended to measure 
displacements less than the 3.0 mm action level in order to avoid performing a couch 
shift.  The recent study by Gill et al.(202) outlined situations when treating RTs may 
be influenced toward not performing couch shifts.  Measurements from a linear 
accelerator with automated couch corrections were significantly greater than those 
for the unit which required manual couch adjustments.  Gill et al.(202) suggested 
that the lack of couch automation may have contributed to the likelihood of 
measurements under the action threshold.  In our study, the RTs utilised the remote 
couch to apply any couch shifts, but were required to perform additional verification 
imaging after any shift.  Therefore the decision to perform a couch shift (measuring 
displacement ≥ 3.0 mm) would have added extra time to the treatment session.  
 
To determine whether the small difference between online and offline observers is 
clinically meaningful, we examined whether the online matching resulted in fewer 
fractions having couch adjustments than were expected from the offline 
measurements.  Overall, there were 147 fractions (65.3 %) where a displacement ≥ 
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3.0mm was measured online.  Similarly, there were 144 fractions (64.0 %) where all 
three offline observers measured a displacement ≥ 3.0 mm, suggesting the online 
observers did not avoid applying couch shifts by aligning below the action level.  
Since the conclusion of this study, we have introduced a 0.0 mm action level within 
our clinic, whereby all displacements are corrected using the remote couch for all 
treatment fractions.   
 
It is possible that the small differences in online and offline measurements were due 
to a limitation of the study whereby image registration was performed in two 
separate software packages with different alignment methods.  All online 
assessments were performed using the Varian OBI software whereas offline 
registration was performed in MOSAIQ.  The online registration consisted of 
overlaying the reference and verification images while offline alignment used curves 
drawn around the FMs on the reference DRR.   
 
Examination of the offline observers alone removes the influence of the online action 
level and any differences in the method of alignment.  Differences between the 
offline observers were smaller than the differences between the online and offline 
observers.  The offline observers demonstrated high degree of agreement, well 
within the ±2.0 mm level predefined for clinical acceptability.  This result further 
demonstrates the consistency of alignment to FMs by RTs.  
3.7. Conclusion 
The results of this study have demonstrated clinically acceptable agreement between 
RTs assessing kV images when matching to FMs.   It has shown that RTs are able to 
accurately and consistently perform prostate IGRT.  It will be important to confirm 
that similar consistency is achieved with volumetric imaging modalities, such as 
cone beam CT.  Potential clinical advantages from the online use of CBCT, such as 
visualisation of the clinical target volume and organs at risk will need to be 
considered in the context of the RTs ability to accurately and consistently interpret 
and align these images. 
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3.9. Additional material 
An example Bland-Altman plot, not included in published article, is included below: 
 
Figure 3.2: Example Bland-Altman plot of interobserver agreement (observer 1 
compared with observer 2) in the (a) superior-inferior, (b) left-right, and (c) 
anterior-posterior directions. 
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4.2. Abstract: 
4.2.1. Introduction 
This investigation aimed to assess the consistency and accuracy of radiation 
therapists (RTs) performing cone beam computed tomography (CBCT) alignment to 
FMs (CBCTFM) and the soft-tissue prostate (CBCTST). 
4.2.2. Methods 
Six patients receiving prostate radiation therapy underwent daily CBCTs.  Manual 
alignment of CBCTFM and CBCTST was performed by three RTs.  Interobserver 
agreement was assessed using a modified Bland-Altman analysis for each alignment 
method.  Clinically acceptable 95 % limits of agreement with the mean (LoAmean) 
were defined as ±2.0 mm for CBCTFM and ±3.0 mm for CBCTST.  CBCTST 
alignment was compared with the mean CBCTFM (AvCBCTFM) alignment.  
Clinically acceptable 95 % limits of agreement (LoA) were defined as ±3.0 mm for 
the comparison of CBCTST and AvCBCTFM. 
4.2.3. Results 
CBCTFM and CBCTST alignments were performed for 185 images.  The CBCTFM 95 
% LoAmean were within ±2.0 mm in all planes.  CBCTST 95 % LoAmean were within 
±3.0 mm in all planes.  Comparison of CBCTST with AvCBCTFM resulted in 95 % 
LoA of -4.9 to 2.6 mm, -1.6 to 2.5 mm, and -4.7 to 1.9 mm in the superior-inferior, 
left-right and anterior-posterior planes respectively. 
4.2.4. Conclusions 
More interobserver variability was found for soft-tissue alignment than for FMs.  
Significant differences were also found between soft-tissue alignment and the 
predicted FM position.  Consideration needs to be given to margin design when 
using soft tissue matching due to increased interobserver variability.  This study 
highlights that soft-tissue guidance is complex and includes numerous uncertainties.   
 
4.2.5. Key Words 
Cone beam computed tomography; Radiotherapy, Image-Guided; Observer 
Variation; Prostate 
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4.3. Introduction 
The importance of ensuring accurate prostate localisation for external beam radiation 
therapy (EBRT) has been widely demonstrated.(51, 109, 170)  Image-guided 
radiation therapy (IGRT) with fiducial markers (FMs) has been shown to provide an 
accurate method of correction for internal prostate motion.(129, 131)  IGRT has 
facilitated dose-escalation by allowing reduced planning target volume (PTV) 
margins.(207)  The use of FMs is generally well-tolerated(19, 121) and has been 
shown to decrease the incidence of acute(208) and late(171) gastrointestinal and 
genitourinary toxicity. 
 
While FM-based IGRT is regarded as safe and efficient, there are associated risks 
and complications.  Trans-rectal implantation of FMs has been shown to cause 
patient discomfort, haematuria, rectal bleeding and infection.(18, 19)  Recently, there 
has been increasing concern regarding risk of multi-drug resistant bacterial infection 
following trans-rectal biopsy or FM insertion.(135, 209)  Some patients are ineligible 
or unwilling to undergo the invasive procedure required, for example due to 
anticoagulant dependence.  Use of FMs can also place financial burden on the clinic 
and patient.  Additionally, since FMs act as a surrogate of prostate position, they do 
not provide direct information regarding surrounding organs-at-risk (OARs). 
 
An alternative IGRT method is cone beam computed tomography (CBCT) which 
provides visualisation of the soft-tissue prostate, seminal vesicles and adjacent 
OARs, at the time of treatment.(146, 210)  CBCT potentially allows accurate 
localisation without the use of FMs. 
 
While it has been shown that RTs consistently align FMs on planar imaging(13, 
211), it is not clear how much variability exists with CBCT-based soft-tissue 
registration.(13)  This study aims to determine whether RTs, who are directly 
responsible for the daily IGRT procedure, are able to consistently and accurately 
align the prostate using CBCT.   
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4.4. Methods 
4.4.1. Patient selection and preparation 
Six patients undergoing radical EBRT for localised prostate cancer between June and 
September 2010 were recruited for this investigation.  The study protocol was 
approved by the Princess Alexandra Hospital Human Research Ethics Committee 
and each patient provided written informed consent. 
4.4.2. Simulation and reference image generation 
Each patient received three intra-prostatic FMs (0.9 x 3.0 mm, CIVCO, Kalona, IA, 
USA), at least 7 days prior to simulation. CT simulation was performed using a 
Siemens Sensation Open (Siemens AG, Erlangen, Germany).  Reference CTs were 
acquired using a 120 kV beam and 3.0 mm slice thickness.  Dosimetry was 
performed in the Pinnacle3 (Philips Healthcare, Eindhoven, the Netherlands) 
radiation treatment planning system. 
4.4.3. Cone beam CT image acquisition method 
Daily CBCTs were acquired using a Varian Clinac iX linear accelerator 
incorporating an On-Board Imager (OBI) (Varian Medical Systems, Palo Alto, CA, 
USA).  CBCTs were acquired with a source voltage of 125 kVp and a source-to-
detector distance of 150 cm.  The CBCT acquisition protocol used a half-fan, half-
bow-tie filter arrangement with a 360 degree gantry rotation.  Reconstruction was 
performed with a 512 x 512 resolution and 2.0 mm slice thickness.  Immediately 
following acquisition of the CBCT, orthogonal planar kilovoltage (kV) images were 
obtained for FM-based treatment localisation. 
4.4.4. Radiation Therapist Observers 
The three observers had between 5 and 15 years’ experience as RTs and 
approximately two years’ experience with planar FM-based IGRT, but had limited 
experience CBCT (<6 months).  The RTs were instructed to perform registrations in 
a clinically relevant timeframe.  In order to approximate the online environment, 
offline CBCT registration was performed at the linear accelerator, using the online 
Varian OBI 3D/3D match software tools (Varian Medical Systems, Palo Alto, CA, 
USA). 
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4.4.5. Fiducial marker localisation (CBCTFM) 
Three RTs independently performed manual co-registration of the FMs on CBCT 
(CBCTFM) with the FMs on the reference CT.  Alignment, without use of rotations, 
was performed offline and the resultant couch translations were recorded. 
4.4.6. Soft-tissue prostate localisation (CBCTST) 
Three RTs independently performed manual alignment of the soft-tissue prostate 
(CBCTST) using the prostate, seminal vesicles, rectum and bladder contours, as 
delineated on the reference CT.  The RTs were restricted to contour-based 
registration in order to minimise bias due to visualisation of FMs on the reference 
CT.  The RTs were able to utilise the transverse, sagittal and coronal plane views, 
and adjust the window/level at any time.  Required couch shifts, without use of 
rotations, were recorded for each CBCT. 
4.4.7. Statistical analysis 
4.4.7.1. Interobserver Agreement: CBCTFM and CBCTST 
To assess agreement between the three observers, couch shifts were compared for 
each of the CBCTFM and CBCTST methods using the process described by Jones et 
al.(204)  In this modified Bland-Altman(187) analysis, each observer was compared 
with the mean shift of all observers.  The modified Bland-Altman analysis 
determined the 95 % limits of agreement with the mean (LoAmean), defined as ±1.96 
x s, where s = the population standard deviation (SD).(204)  Agreement plots 
providing a visual assessment of interobserver variability were created.(204)  The 
mean, SD and range of measurements for each observer were also calculated.  
Calculations were performed using Microsoft Excel 2010 (Microsoft, Redmond, 
WA, USA).  To assess the clinical significance of the interobserver agreement, a 
threshold for acceptability was set at 95 % LoAmean ≤ ±2.0 mm for CBCTFM and ≤ 
±3.0 mm for CBCTST.  The ±2.0 mm CBCTFM acceptability threshold was based on 
knowledge of alignment of FMs on planar imaging.(211)  The ±3.0 mm threshold for 
CBCTST was equivalent to the departmental online action level.  We report 
agreement within ±2.0 mm and ±3.0 mm for each method. 
 
 Chapter 4: Assessment of cone beam CT registration for prostate 
radiation therapy: fiducial marker and soft-tissue methods 
76 
 
4.4.7.2. Method Comparison: CBCTST and CBCTFM 
To assess accuracy of the soft-tissue localisation method, the CBCTST results were 
compared with the established standard of FM alignment using the method described 
by Bland and Altman(187) for comparing two methods of measurement.  The 
baseline FM position was estimated by obtaining the mean of the CBCTFM position 
from the three observers for each fraction (AvCBCTFM).  Bland-Altman analysis 
determined the mean and SD of the method differences.  The 95 % limits of 
agreement (LoA), defined as the mean of the differences ± 1.96 times the SD of the 
differences, were also calculated.(187)  Calculations were performed using Analyse-
It® software (Method Evaluation Edition, Analyse-It Software Ltd, Leeds, UK).  To 
assess whether CBCTFM and CBCTST could be considered interchangeable, a 
threshold for clinical acceptability was set at 95 % LoA ≤ ±3.0 mm. 
4.5. Results 
Six prostate adenocarcinoma (T1c to T2b) patients underwent radical EBRT between 
June and September 2010.  Their median age was 69.6 years (Range: 61.2 to 74.7 
years) and average prostate volume was 36.4 cm3 (Range: 20.5 to 56.7 cm3).  A total 
of 227 fractions were delivered.  CBCTs were not acquired for 16 fractions (7.0 %) 
due to hardware issues or workload constraints.  An additional 26 CBCTs (11.5 %) 
were not saved locally within the OBI system and were unavailable for offline 
review.  Overall, 185 (81.5 %) of the possible 227 CBCTs were included in the 
analysis. Each patient had between 29 and 33 CBCTs included. 
4.5.1. Interobserver agreement: CBCTFM 
The FMs were easily visualised on all CBCTs, except four fractions where distortion 
of FMs due to motion during image acquisition was observed.  An example of 
adequate visualisation is shown in Figure 4.1 and FM distortion in Figure 4.2.   The 
mean, SD and range of the CBCTFM alignment for each observer in each plane are 
shown in Table 4.1.  Modified Bland-Altman agreement plots of CBCTFM are shown 
in Figure 4.3.  The 95 % LoAmean were within the predetermined clinically 
acceptable limit of ±2.0 mm in all planes.  Interobserver agreement was best in the 
LR direction where the 95 % LoAmean was calculated to be ±0.8 mm.   The 95 % 
LoAmean in the SI and AP planes were ±1.1 mm and ±1.2 mm respectively.  The 
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percentage of observer-pair agreement within 2.0 mm was 98.7 %, 100.0 % and 97.7 
% in the SI, LR and AP directions respectively.  The percentage of observer-pair 
agreement within 3.0 mm was 99.8 % (SI), 100.0 % (LR) and 99.3 % (AP). 
 
 
Figure 4.1:  Example of a good quality CBCT, demonstrating adequate visualisation 
of the soft-tissue anatomy in the (a) transverse; (b) coronal; and (c) sagittal planes.  
One of the fiducial markers can be seen in (a). 
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Figure 4.2:  Example of artefacts seen in the CBCTs.  Distortion of the soft-tissue 
anatomy and FMs is caused by moving gas in the rectum.  The posterior border of 
the prostate is poorly defined due to the artefact. 
 
 
Table 4.1: Description of alignments to fiducial markers on cone beam CT 
(CBCTFM).  Negative values represent superior, left and posterior directions. 
Plane Observer Mean (mm) 
SD 
(mm) Range (mm) 
SI 
1 -0.5 2.1 -7.0 to 5.0 
2 -0.8 2.3 -8.0 to 4.0 
3 -0.5 2.1 -7.0 to 4.0 
LR 
1 0.4 2.3 -5.0 to 8.0 
2 0.5 2.3 -6.0 to 8.0 
3 0.5 2.4 -5.0 to 8.0 
AP 
1 -0.3 2.6 -7.0 to 9.0 
2 0.1 2.6 -6.0 to 10.0 
3 -0.2 2.7 -8.0 to 11.0 
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Figure 4.3:  Modified Bland–Altman plots demonstrating the 95% limits of 
agreement with the mean (LoAMean) for multiple observers aligning to fiducial 
markers (cone beam computed tomography alignment to fiducial markers) 
(CBCTFM)) in the superior–inferior (SI), left–right (LR) and anterior–posterior (AP) 
planes (a, c, and e, respectively). The plots for CBCT alignment to soft tissue 
prostate (CBCTST) are shown in the SI, LR and AP planes (b, d, and f, respectively 
X, Observer 1; ●, Observer 2; ▲, Observer 3; ―, 95% LoAMean; - - -, clinically 
acceptable threshold. 
 
 Chapter 4: Assessment of cone beam CT registration for prostate 
radiation therapy: fiducial marker and soft-tissue methods 
80 
 
4.5.2. Interobserver agreement: CBCTST 
The mean, SD and range of the CBCTST alignment for each observer in each plane 
are shown in Table 4.2.  Modified Bland-Altman comparisons of CBCTST are plotted 
in Figure 4.3.  The 95 % LoAmean results were within the predefined clinically 
acceptable of ±3.0 mm in all planes.  Interobserver agreement was again best in the 
LR direction where the 95 % LoAmean was calculated to be ±1.5 mm.  The 95 % 
LoAmean in the SI and AP planes were ±2.5 mm and ±2.0 mm respectively.  The 
percentage of observer-pair agreement within 2.0 mm was 76.0 %, 94.6 % and 84.1 
% in the SI, LR and AP directions respectively.  The percentage of observer-pair 
agreement within 3.0 mm was 90.6 % (SI), 98.9 % (LR) and 95.0 % (AP). 
 
Table 4.2: Description of alignments to soft-tissue on cone beam CT (CBCTST). 
Negative values represent superior, left and posterior directions. 
Plane Observer Mean (mm) 
SD 
(mm) Range (mm) 
SI 
1 0.4 2.2 -6.0 to 10.0 
2 0.2 1.6 -5.0 to 4.0 
3 1.0 2.0 -5.0 to 8.0 
LR 
1 0.3 2.2 -5.0 to 8.0 
2 0.1 2.0 -5.0 to 6.0 
3 -0.3 2.4 -8.0 to 9.0 
AP 
1 1.2 2.3 -5.0 to 9.0 
2 1.2 1.8 -3.0 to 10.0 
3 1.4 2.1 -4.0 to 10.0 
 
4.5.3. Method Comparison: CBCTST and CBCTFM 
The results of Bland-Altman comparison of CBCTST and CBCTFM are shown in 
Table 4.3.  Mean differences between CBCTST and CBCTFM indicated that the RTs 
tended to systematically match the soft-tissue 1.1 mm more inferior and 1.4 mm 
more anterior than predicted by the FM position. 
 
The 95 % LoA were within the clinically acceptable range of ±3.0 mm in the LR 
plane, but were -4.9 to 2.6 mm in the SI plane and -4.7 to 1.9 mm in the AP 
direction.  The percentage of CBCTFM and CBCTST agreement within 3.0 mm was 
86.3 %, 99.6 % and 84.7 % in the SI, LR and AP directions respectively.  At least 
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two of the three RTs measured CBCTST within 3.0 mm of AvCBCTFM on 91.9 %, 
100.0 % and 89.2 % of fractions in the SI, LR and AP planes respectively.  There 
were 8 (4.4 %) fractions where all three observers differed from the AvCBCTFM 
position by ≥ ± 3.0 mm in the SI or AP plane. 
 
Table 4.3: Bland-Altman comparison of alignment of the soft-tissue prostate 
(CBCTST) compared with the mean fiducial marker position from the three observers 
(AvCBCTFM). 
Direction 
Mean of 
differences 
(mm) 
SD of 
differences 
(mm) 
Lower 95 % 
LoA (mm) 
Upper 95 % 
LoA (mm) 
SI -1.1 1.9 -4.9 2.6 
LR 0.4 1.0 -1.6 2.5 
AP -1.4 1.7 -4.7 1.9 
4.6. Discussion 
Prostate localisation using FMs is an efficient IGRT technique, requiring minimal 
imaging dose and time compared with other modalities.(163, 168, 182)  However, 
not all patients are candidates for insertion of FMs and an alternative IGRT solution, 
such as soft-tissue localisation using CBCT, may be required for this cohort.  This 
study compared RTs aligning to FMs and soft-tissue on CBCT.  While the 95 % 
LoAmean were within the predefined clinically acceptable thresholds of ±2.0 mm and 
±3.0 mm for CBCTFM and CBCTST respectively, the soft-tissue alignment 
interobserver variability was much greater than for FM-based alignment.  Soft-tissue 
alignment differed from the FM position by more than the clinically acceptable 
threshold of ±3.0 mm in the SI and AP planes. 
 
CBCTFM localisation resulted in minimal interobserver differences.  The 
unambiguous nature of FMs means little interpretation is required to determine their 
position.  The magnitude of interobserver variability from CBCTFM alignment was 
similar to that previously measured for alignment to FMs on planar imaging(211), 
demonstrating that RTs are able to consistently align FMs on either planar or 
volumetric imaging. 
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While our comparison of FM and soft-tissue alignment resulted in variability in 
excess of the predefined clinically acceptable limits, the results do compare 
favourably with other published data.  In a comparison of CBCTST and CBCTFM, 
Moseley et al.(13) reported 95 % LoA in excess of 5.0 mm in the SI and AP planes.  
Moseley’s results were similar to our current study in the LR plane and interobserver 
variability was considered the largest source of uncertainty for soft-tissue alignment.  
Despite large differences between soft-tissue and FM alignment, Moseley concluded 
that CBCT was an accurate means of soft-tissue IGRT provided that PTV margins in 
the order of 10.0 mm were maintained.  For their comparison of soft-tissue and FM 
alignment, Barney et al.(182) defined acceptable differences to be within their PTV 
margin of 5.0 mm, which was only achieved in the LR plane.  Barney concluded that 
planar imaging with FMs was the preferred IGRT method.  Temporal differences 
could account for some of the inconsistency in Barney’s results as the FM position 
was obtained from planar imaging rather than CBCT.  As shown by these two 
studies, the clinical acceptability of soft-tissue localisation with CBCT is largely 
dependent on the size of PTV margins.  Subsequently, PTV margins need to be 
appropriate tailored to account for the uncertainties of different localisation methods 
to be used. 
 
The larger interobserver variability found for CBCTST compared with CBCTFM 
alignment can be attributed to CBCT image quality, which is generally inferior to the 
reference CT and is affected by low contrast-to-noise ratio, motion artefacts due to 
the long image acquisition time and moving gas-induced artefacts.(110, 155, 212)  
Subsequently, it can be difficult to distinguish the soft-tissue prostate from adjacent 
structures, particularly at the base and apex due to similar densities (e.g. rectum, 
bladder, muscles).(199, 200) 
 
Comparison of CBCTST and CBCTFM is difficult since there is no “ground-truth” for 
the prostate position.  Since FMs are the accepted gold-standard method for prostate 
localisation, the FM position has been accepted as the truth in this study.  This 
assumption belies the fact that the prostate can deform relative to FMs.(102)  It is 
possible that some of the differences between CBCTST and CBCTFM may be because 
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the FM position did not accurately reflect the prostate position rather than because of 
poor soft-tissue localisation. 
 
The use of contour-based alignment within this study may have contributed to 
CBCTST alignment variability.  The underlying reference CT was not used in order 
to reduce the influence of the FMs.  While Court et al.(198) found contour-based 
alignment was sufficiently accurate and use of the reference CT made only small 
improvements to interobserver consistency, contour-based registration precludes use 
of distinctive anatomical landmarks such as intraprostatic calcifications which have 
been shown to be advantageous in prostate alignment.(213)  Clinically, use of the 
reference CT may improve CBCTST interobserver agreement. 
 
While the position of FMs on the reference CT was unknown to the RTs, 
visualisation of FMs on the CBCTs may have aided soft-tissue alignment since the 
FMs are indicative of prostate position.    We were unable to remove FMs from the 
projection data as has been done in other studies.(13, 199)  The variation between 
CBCTFM and CBCTST may be underestimated due to the presence of FMs in the 
CBCTs.  The large differences observed between CBCTFM and CBCTST suggest it is 
unlikely that the FMs did cause such a bias.  In contrast, it is possible that artefacts 
caused by the FMs distorted the boundary of the prostate, causing a source of 
alignment uncertainty. 
 
The number of observers included in this study was limited due to the time required 
for CBCTFM and CBCTST registrations by each observer.  Inclusion of more RTs 
may have resulted in more precise estimation of interobserver variability for each of 
the CBCTFM and CBCTST strategies.  The finding that soft-tissue alignment has 
greater interobserver variability than matching FMs is unlikely to change with more 
observers. 
 
It is possible that the sample size of six patients meant the RTs became familiar with 
anatomical features when performing soft-tissue registration, thereby increasing the 
consistency of alignment.  Study design may have been improved by including more 
patients and fewer images per patient.  Internal prostate motion and variations in 
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rectal and bladder size can, though, reduce this effect.  The differences between 
CBCTFM and CBCTST would be unlikely to change significantly with increased 
sample size. 
 
The introduction of soft-tissue alignment has several workflow and training 
implications.  Since at least one observer aligned CBCTST within 3.0 mm of the 
CBCTFM position on 95.6 % fractions, we recommend that two RTs perform 
localisation. This practice may serve to improve consistency of soft-tissue alignment.  
The RTs participating in this study had limited prior experience performing CBCTST 
prostate localisation.  This may partly explain the interobserver variation found.  As 
RTs gain more experience with CBCTST it is reasonable to expect that observer 
agreement will improve.  Sahota et al.(214) identified the use of anatomy atlases as a 
means of improving the ability and confidence of RTs to identify structures on post-
prostatectomy CBCTs.  White et al.(199) also recommended training RTs in image 
guidance and image recognition as well as development of IGRT protocols in order 
to reduce the risk of localisation errors.  Since the conclusion of this investigation, 
we have sought to reduce CBCTST interobserver variability by developing in-house 
training to improve knowledge and understanding of anatomy and IGRT decision-
making. 
4.7. Conclusion 
This study quantifies the interobserver variability when RTs align FMs or soft-tissue 
on CBCT.  It also directly compares CBCT localisation based on soft-tissue and 
FMs.  Interobserver variability was considerably greater for soft-tissue alignment 
compared with FMs.  Large differences between soft-tissue localisation and FM 
position were found.  The implementation of soft-tissue guidance protocols should 
only be performed with the understanding that localisation results can differ between 
IGRT modalities.  Incorporating the results of an evaluation of local IGRT 
performance into margin calculation is necessary to ensure the risk of geometric miss 
is minimised.  This study adds to the evidence that IGRT is complex and includes 
numerous uncertainties. 
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Chapter 5: Discussion  
5.1. Discussion 
IGRT is an essential part of the radiation therapy process and is critical to ensuring 
accurate dose delivery.  It is important for each radiotherapy department to ensure 
their IGRT processes are of high quality.(215) This investigation of IGRT methods 
coincided with the introduction of new IGRT technology within ROMC.  It was 
designed to compare two forms of IGRT for prostate EBRT, i.e., planar kV imaging 
using FMs and soft-tissue localisation with CBCT.  The purchase of two new linear 
accelerators (linacs) with the capability for kV imaging (planar and volumetric) 
resulted in the replacement of two units which had no electronic imaging capability, 
and had therefore relied on film-based verification.  Two other linacs within the 
department utilised low resolution ion chamber EPIDs for treatment localisation.  
The availability of new imaging technology presented an opportunity to critically 
assess and improve IGRT methods. 
 
The primary aim of this investigation was to compare prostate localisation with 
planar and volumetric kV imaging in terms of localisation agreement and 
interobserver variability.  This was motivated by the desire to determine whether 
CBCT could be used to accurately and consistently align the prostate, without the 
use of FMs.  In order to determine the consistency of prostate IGRT, with and 
without FMs, multiple RTs were asked to align either FMs or soft-tissue on planar 
and volumetric imaging.  The isocentre placement from FMs and soft-tissue was 
compared to determine how well each IGRT method agreed.  Interobserver 
agreement was also determined for each IGRT method. 
 
The first aim of this research was to compare the isocentre localisation results from 
soft-tissue alignment using CBCT with the localisation from alignment to FMs.  Our 
results demonstrated considerable differences between these methods, discussed 
further in Section 5.1.3.  A further aim of this investigation was to evaluate the 
consistency of RTs aligning to FMs on planar kV imaging.  Excellent interobserver 
agreement was found in both the online and offline workflows, supporting the 
widespread use of this technique (discussed further in Section 5.1.1.).  An additional 
aim was to determine the consistency of RTs aligning to soft-tissue on volumetric 
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kV CBCT imaging.  While large interobserver variations where found for the soft-
tissue alignment, the use of FMs was observed to improve interobserver agreement 
when performing kV CBCT-based IGRT (Discussed in Section 5.1.2.). 
 
Measurement of agreement with either the Bland-Altman(20, 187) or Jones(204) 
methods relies on the assumption that (i) no relation exists between the difference 
and mean; and (ii) the differences follow a normal distribution.  Each of these 
assumptions was satisfied in the calculation of results for Chapters 3 and 4. 
5.1.1. Interobserver variability: FMs  
Prostate localisation based on FMs has become the standard of care in Australia and 
internationally.(16, 215)  The results of this investigation support the use of FMs as a 
surrogate of prostate position by demonstrating excellent interobserver agreement for 
RTs’ alignment to FMs on planar kV imaging and on kV CBCT.  RTs were able to 
align FMs within the clinically acceptable thresholds on either planar (±2.0 mm 95% 
LoA) or volumetric imaging (±3.0 mm 95% LoA), as well as in the online and 
offline environment. 
 
The transition from localisation using bony anatomy to FM-based guidance was, in 
technical terms, relatively simple.  Prior to the introduction of FM-based IGRT at 
ROMC, the RTs had become proficient with the hardware and software used for 
planar kV imaging based on bony anatomy.  Since the RTs also had been performing 
MV planar imaging with ion-chamber EPIDs for many years the improved image 
quality was welcomed when performing online corrections.  In terms of image 
acquisition and review, the process for FM-based IGRT was similar to that used for 
bony alignment.  The use of FMs can be considered a simplification of the image-
guidance process compared with bony alignment since it relies on three discrete 
points rather than interpretation of several bony landmarks.   
 
The finding that RTs are able to register FMs with high consistency is supported by 
recent literature, some published since the initiation of this study.  Chung et al., has 
reported that the majority of RTs consider alignment of FMs using planar imaging 
can be performed with ease.(126)  Kong et al. demonstrated that alignment to FMs 
was performed with much less interobserver variability than alignment to bony 
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anatomy.(196)  The excellent agreement between online and offline observers found 
in the current study highlights that RTs are able to accurately perform FM 
localisation with kV planar imaging under the pressure of the online environment. 
 
In order to better compare the results from Chapter 3 and Chapter 4, we can 
recalculate the Chapter 3 interobserver agreement according to the modified Bland-
Altman analysis described by Jones et al. used in Chapter 4.  This method of 
comparing multiple observers was unknown to us at the time of preparing the 
investigation of planar imaging (Chapter 3).  Using the data from the offline 
observers, calculation of interobserver agreement in terms of 95 % LoAmean for kV 
planar imaging is demonstrated in Table 5.1. 
 
Table 5.1: 95 % LoAmean for various IGRT methods 
Alignment Method SI (mm) 
LR 
(mm) 
AP 
(mm) 
kV planar: FMs† 0.8 0.7 0.9 
kV CBCT: FMs‡ 1.1 0.8 1.2 
kV CBCT:  soft-tissue‡ 2.5 1.5 2.0 
†recalculated from Chapter 3 results 
‡as published in Chapter 4
 
Interestingly, we have found that interobserver variability for alignment of FMs is 
slightly greater on CBCT than for planar imaging (see Table 5.1).  This is likely due 
to differences in the image acquisition process between planar and volumetric 
imaging, and also due to differences in the process of reviewing these images.  Since 
planar imaging is acquired with millisecond exposures, the FMs are well defined 
with sharp edges.  The longer acquisition time of CBCT increases the likelihood of 
motion blurring and the FMs on CBCT are less sharp.  Examples of FMs imaged 
with planar and volumetric images are shown in Figure 5.1.   
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Figure 5.1: (a) planar image of FMs; (b) axial slice of CBCT demonstrating 
distortion of FM.  The FM is distorted in the CBCT due to motion during the 
relatively longer image acquisition with respect to planar imaging. 
 
When performing image registrations within this study, the observers remarked that 
it was easier to evaluate the “best-fit” of the three markers on planar imaging.  
Alignment of the FMs on CBCT was found to be more subjective since the FMs 
could not be evaluated simultaneously.  When comparing alignment of FMs on kV 
planar and CBCT images, Owen et al. also found that differences in the nature of 
planar and volumetric image review contributed to differences in localisation 
position.(181) 
5.1.2. Interobserver variability: soft-tissue 
Alignment to the soft-tissue prostate was found to result in considerably greater 
interobserver variability compared with alignment to FMs.  It is likely that factors 
such as image quality, patient characteristics and the nature of the observers all 
contribute to the interobserver variability found in this investigation.  The degree of 
interobserver variability found in this study adds to the evidence that the image 
quality of CBCT results in highly subjective interpretation of the soft-tissue.   
 
The reduced image quality of CBCT has been identified by Stock et al., who found 
contrast-to-noise ratio was, on average, 51 % higher for CT than for CBCT.(212)  
The lack of collimation inherent in CBCT also results in poorer low-contrast-
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visibility which is relevant for differentiating soft-tissue structures.(212)  CBCT also 
suffers from a relatively long image acquisition time which can lead to image 
blurring subsequent to patient and organ motion.  Of particular relevance in prostate 
CBCTs is the potential for moving bowel gas resulting in degraded image quality.  
As a result of the poor CBCT image quality, there is significant difficulty discerning 
the prostatic base and apex.  This is also the case of diagnostic quality FBCT. 
 
As evidenced by delineation studies, the reduced image quality of CBCT leads to 
significant uncertainty in visualisation of the prostate.(199, 200)  White et al. found 
that prostate delineation on CBCT was complicated by difficulty locating the 
interface between the prostate and peri-prostatic tissue which led to large 
interobserver differences for the definition of prostate boundaries.  Similar to our 
results, the largest differences were in the SI plane, most probably due to difficulty in 
distinguishing the prostate base and apex.  Since our localisation technique relied on 
placing the reference contours on the CBCT image, the RTs were essentially 
localising the prostate boundaries.   
 
Overall, interobserver agreement was best in the LR direction.  Prostate delineation 
studies have also shown the least variability in this plane.  Visualisation of the 
prostate boundaries in an axial plane is aided by adjacent muscles such as the levator 
ani and obturator internus.  Even without the use of the underlying reference CT, as 
in this study, these muscles can be identified relatively easily and reduce the 
uncertainty of prostate position in the lateral direction. 
 
The least interobserver agreement was found in the SI direction where it has been 
noted the prostate base and apex are difficult to visualise, even on FBCT.(216)  The 
bladder base is a poor surrogate for prostate position in the SI direction since its 
shape deforms with differential filling.  The AP placement of the prostate is 
somewhat aided by visualisation of the anterior rectal wall.  When placing the 
prostate contour, the seminal vesicle contours could be used to confirm SI 
placement, but only in the absence of deformation.  The seminal vesicles were often 
difficult to visualise due to artefacts from gas in the rectum, or they shifted relative 
to the prostate with variable bladder and rectal filling.  Changes in bladder and rectal 
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volume will displace the seminal vesicles, and often they are difficult to visualise on 
CBCT in presence of gas-induced artefacts.  
 
While the study was not designed to compare the localisation results between 
patients, it is useful to review the results for each patient to better understand some 
of the patient factors which may have contributed to interobserver variability, see 
Table 5.2. 
Table 5.2:  95 % LoAmean CBCTST interobserver variability (per-patient basis) 
Patient SI (mm) LR (mm) AP (mm) 
7 1.7 1.2 1.8 
8 2.1 1.5 2.0 
9 2.2 1.3 2.1 
10 3.5 2.1 2.0 
11 2.8 1.5 1.9 
12 2.2 1.0 2.1 
 
A closer examination of the characteristics of Patient 7 may help to explain some of 
the factors which aid in good interobserver agreement for soft-tissue localisation.  
The interobserver agreement was within 2.0 mm in all planes for this patient.  It is 
noteworthy that they had some unique features which probably aided the registration 
consistency.  Figure 5.2 illustrates the asymmetric shape of Patient 7’s prostate.  The 
RTs performing soft-tissue localisation noted that the irregular shape was easy to 
visualise on CBCT and therefore the contour was able to be aligned with 
consistency.  It is also likely that the irregular nature of this patient’s prostate 
anatomy helped to verify the placement of the prostate in the SI direction.  While 
many prostates have a regular shape from base to apex, the variable shape of Patient 
7 reduced alignment discrepancies.  Figure 5.2 also illustrates that there was 
identifiable space between the rectum and prostate over several slices, with clear 
differentiation in grey-scale, which assisted in AP placement of the prostate. 
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Figure 5.2: Reference CT for Patient 7 – note asymmetric nature of prostate (red 
contour), extending posteriorly adjacent to right side of the rectum (brown 
contour). 
 
Conversely, Patient 10 had considerably more interobserver variability than the other 
patients, particularly in the SI plane.  It is probable that Patient 10’s history of 
transurethral resection of the prostate (TURP) led to difficulty determining the 
interface between the prostate and bladder, and therefore caused increased 
interobserver variability in SI direction. Axial and sagittal CBCT images for Patient 
10 through the TURP region are shown in Figure 5.3. 
Interobserver variability is likely to be influenced by the level of experience and 
expertise of the RTs performing the IGRT.  Each of the observers included in this 
study had considerable experience as RTs (> 5 years), yet none had clinical 
experience with using CBCT for soft-tissue guidance.  They had limited (< 6 
months) experience with non-clinical use of the system, and also had experience 
with multi-modality soft-tissue registration for the purpose of treatment planning. 
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Figure 5.3: Reference CT for Patient 10.  An axial slice is shown on the left and 
sagittal slice on the right.  Previous history of TURP can be seen to negatively 
impact visualisation of the boundary between the prostate and bladder. 
 
It is highly likely that increased experience will reduce the amount of intra- and 
interobserver variation in image interpretation and therefore localisation.  White et 
al. argued that structured staff education was a vital prerequisite for soft-tissue based 
IGRT.(199)  As IGRT evolves from planar to volumetric imaging, it is important to 
ensure that users are supported in developing the necessary knowledge and skills.  
With the introduction of volumetric imaging at ROMC, many RTs expressed a lack 
of confidence when performing soft-tissue prostate alignment.  It could be 
considered that they changed from “experts” with planar imaging to “novices” when 
performing volumetric IGRT.  The process of replacing four linacs in a relatively 
short time impacted the ability to offer training with the online IGRT tools.  The 
access to linacs was curtailed by the clinical hours.  With any one linac out of 
operation, the remaining three machines operated from 7.30am to 9.00pm, leaving 
no access to the Varian software within clinic hours.  The only image review 
software available was MOSAIQ which did not closely resemble the online 
environment.   Since completion of this investigation, access to the linacs is no 
longer an issue.  In order to gain proficiency, the RTs have since benefitted from a 
structured approach to image review, whereby clinical reasoning is supported by 
training using online and offline tools.  The online workflow is also supported by 
decision-trees which describe the agreed method of alignment and include trouble-
shooting tips.  For instance, the RTs are guided as to the appropriate course of action 
when the rectum is distended and the prostate is rotated or difficult to visualise on 
CBCT. 
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While appropriate education is important in ensuring quality IGRT, it should be 
recognised that there are inherent limitations which cannot be remedied by training.  
The significant contouring variability of several highly experienced ROs found by 
White et al. suggests that even with extensive experience, the image quality of 
CBCT compromises delineation of the prostate boundaries.(199)  Based on these 
results, White et al. has recommended rigorous training for RTs to reduce operator 
variability of soft-tissue guidance, but the findings of Morrow et al. demonstrate that 
the reduced quality of CBCT images is the major factor contributing to greater 
variability of soft-tissue registration compared with FBCT.(155)  Until CBCT image 
quality improves, even with the best training, soft-tissue localisation with CBCT will 
have more uncertainty compared with FBCT.  According to Moseley et al., 
interobserver variability can be considered the largest source of uncertainty for soft-
tissue alignment with CBCT.(13) 
 
As demonstrated by the increased interobserver variability of aligning FMs on 
CBCT compared with planar imaging, the nature of volumetric imaging requires 
greater observer interpretation.  This is magnified when performing soft-tissue 
alignment since there are infinitely more “data points” to assess compared with three 
discrete FMs.  When aligning FMs on planar imaging, each of the three FMs can be 
assessed simultaneously.  Alignment on CBCT, though, requires the RTs to assess 
the best-fit by evaluating the prostate contour on multiple slices in three planes.  It is 
a more time-consuming process, requiring more deliberation to ensure an appropriate 
overall “best-fit” compromise is obtained. 
5.1.3. Comparison of FMs and soft-tissue localisation 
The comparison of soft-tissue and FM-based localisation demonstrated differences 
greater than the predefined clinically acceptable 95 % LoA of ± 3 mm.   It is 
important to understand that localisation with soft-tissue may not result in isocentre 
placement equivalent to that found for FM registration.  Agreement between soft-
tissue alignment and FMs was strongest in the LR plane compared with the SI and 
AP planes.  Similar large differences between soft-tissue localisation and FMs in the 
SI and AP planes were found by Moseley et al. and Barney et al.(13, 182)  It is 
likely that the difficulty in visualisation the prostate base and apex on CBCT 
negatively impacts the accuracy and consistency of soft-tissue localisation.  One of 
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the primary reasons soft-tissue guidance differs from FM-based localisation is the 
poor image quality of CBCT causes uncertainty in defining soft-tissue 
boundaries.(155, 199, 200)   
 
Many of the factors which contributed to the significant interobserver variability of 
soft-tissue matching, as outlined above, are also responsible for differences between 
FMs and soft-tissue alignment.  The increased interobserver variability for 
localisation of FMs on CBCT compared with planar imaging (see Table 5.1) 
suggests that greater observer interpretation is required to perform alignment with 
volumetric data.  As described above, the method of scrolling through several slices 
to visualise each FM and adjust the best-fit alignment leads to greater variability of 
alignment to FMs compared with visualising all three FMs at once on a planar 
image. 
 
It is important to recognise that it may be imprecise to consider FMs as the absolute 
truth for prostate position when comparing the alignment of soft-tissue and FMs.  
Prostate localisation based on FMs has its own uncertainties, such as from marker 
migration, prostate deformation and rotation. Nichol et al. have demonstrated that 
prostate shape and size can alter relative to intraprostatic FMs.(102)  Therefore, 
alignment of the prostate contour on the CBCT may be influenced by changes in 
prostate dimension which is not reflected in the FM position. 
 
Moseley et al. found sufficient agreement between FM position on planar imaging 
and CBCT to conclude that they are an equivalent means of isocentre correction for 
patients with FMs.(13) When comparing localisation with and without FMs, the 
agreement between soft-tissue localisation and FMs on CBCT was less strong, and 
the differences found by Moseley et al. were larger than for the current study.(138)  
This was attributed to the well-established difficulty in locating prostate boundaries 
on CT.(216, 217)  Moseley et al. stated that, as long as PTV margins in the order of 
10 mm are maintained, it is safe to use CBCT for prostate localisation without FMs.  
Other centres, though, have pursued tighter margins.  In their comparison of soft-
tissue alignment and FMs, Barney et al. found that differences in localisation would 
affect target coverage in over one-quarter of fractions when using a 5.0 mm 
margin.(182)  Differences between FMs and soft-tissue were probably exaggerated 
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in this study by use of FM position on planar imaging rather than CBCT, resulting in 
the potential for motion between images.  Since Barney et al. required a radiation 
oncologist to be present for each CBCT-guided treatment the use of soft-tissue 
localisation resulted in considerable resource implications.  Planar imaging was their 
preferred method of IGRT due to their choice of relatively small margins, the 
relative speed of imaging, reduced imaging dose, and reduced reliance on radiation 
oncologists.(182)  Our findings, as well as those of Moseley and Barney demonstrate 
it is important to consider larger PTV margins when using soft-tissue guidance 
compared with FMs. 
 
There are several measures which may improve the accuracy of soft-tissue IGRT and 
reduce interobserver variability compared with the results of this investigation.  A 
major factor in the large interobserver variability found for soft-tissue alignment in 
this study may have been because the RTs were unable to refer to the planning CT 
image.  Court et al. found that use of the reference CT improved registration 
accuracy compared with a contour-based alignment.(198)  It is expected that use of 
the reference CT in conjunction with the contours will improve localisation 
accuracy.  Use of the reference CT will allow RTs to identify features such as 
intraprostatic calcifications which may help refine soft-tissue prostate 
alignment.(213) 
 
In order to reduce the inconsistency between RTs, it is attractive to consider the use 
of automatic registration algorithms to perform registration independent of the 
operator.  It is not clear, though, whether the use of automated methods improves 
consistency compared with manual alignment.  Using an experimental algorithm, 
Smitsmans et al. found that automatic grey-value registration was highly successful 
compared with manual registrations.(158)  Conversely, Shi et al. found that soft-
tissue based automatic corrections were inappropriate as they resulted in large 
difference with the FM position and were highly influenced by bony anatomy within 
the match volume.(183)  Fonteyne et al. also found that automatic registrations did 
not agree with soft-tissue anatomy as they were detrimentally impacted by bony 
anatomy.(186)  While Shi et al.(183)  recommended the use of manual alignment to 
FMs, Fonteyne et al.(186) suggested that it was important to ensure manual 
adjustment of soft-tissue alignment. 
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While this study has compared FMs and soft-tissue IGRT on the basis of isocentre 
localisation, there are several other factors to consider.  Chief amongst these is the 
risk of serious complication from the insertion of FMs.  While the TRUS-guided 
placement of FMs is considered tolerable and safe, there is a real risk of infectious 
complications.  This risk has been heightened by the increasing incidence of multi-
drug resistant E. coli.(135, 209)  Additionally, patients dependent on anticoagulants 
are often deemed ineligible for insertion. 
 
When considering the relative worth of CBCT over planar imaging, it is important to 
consider the visualisation of normal tissue.  While the principal aim of IGRT is to 
correct for variations in target position, the OARS are also likely to vary in size, 
shape and position.  These target and OAR changes do not necessarily coincide.  
Correction for target position may therefore lead to overdosing of the adjacent 
normal tissue.  In order to reduce toxicity from dose-escalated EBRT, visualisation 
of the normal tissues may be as important as seeing the target.  Ultimately, CBCT 
provides extra information related to the size, shape and position of the target and 
OARs which is not readily available with planar imaging. 
 
An important advantage of CBCT over planar imaging is the additional information 
obtained by visualisation of the soft-tissue target and OARs.  CBCT provides an 
assessment of the size and shape of the targeted prostate and seminal vesicles.  Since 
it is not routine practice, for most centres, to insert FMs in the seminal vesicles, it is 
difficult assess their motion with planar imaging.  FMs are also limited in their 
ability to demonstrate prostate rotations compared with CT.(105)  Visualisation of 
the bladder and rectum with CBCT is useful in ensuring compliance with patient 
preparation protocols designed to reduce motion and limit toxicity.   For instance, 
RTs are able to compare the bladder volume seen on CBCT with the planned volume 
and provide the patient with feedback to ensure adequate bladder sparing, and 
potentially, small bowel avoidance.  Rectal distension due to either solids or gas can 
be easily assessed on CBCT, whereas planar imaging is only sensitive to gas pockets 
indicating distension. 
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With planar imaging using FMs, the RTs are required to infer the appropriateness of 
localisation by how easily the FMs are aligned.  For instance, if the three markers 
can all be aligned without compromise, it is highly likely the prostate is well 
matched.  If the markers are difficult to align, for example because of rotation, the 
RTs are required to make a judgement whether the match is appropriate.   
 
Another important consideration in the comparison of these IGRT methods is 
imaging dose.  Daily imaging with CBCT can result in a significant cumulative 
imaging dose.(163, 164)  While dose from CBCT is comparable to that from 
traditional planar MV imaging(166), a major advantage of kV planar imaging is the 
extremely low dose required.(163, 166) 
5.2. Future prostate IGRT directions 
It is highly likely that CBCT image quality will continue to improve with advances 
in hardware and reconstruction algorithms.  Since performing this investigation, 
CBCT image quality has been improved within our department by updating from 
Varian “Exact” to “IGRT” treatment couches.  The acquisition of these new carbon-
fibre couches has helped reduced artefacts from the couch rails.  Ding et al. has 
demonstrated considerable image quality improvements due to version updates from 
the Varian “OBI” to “TrueBeam” platforms.(168)  While the image quality more 
closely resembles that from FBCT, the TrueBeam advances have also resulted in a 
reduction in imaging dose.(168)  Such improvements may lead to reduced 
interobserver variability and increased accuracy when performing soft-tissue 
localisation.  As the CBCT more closely resembles the quality of FBCT, it is likely 
that CBCT-based delineation of the prostate for adaptive replanning will be aided by 
such improvements.  While soft-tissue visualisation on CBCT should improve in the 
future, it is also likely that intraprostatic FMs will remain instrumental in prostate 
IGRT, especially in the context of a number of emerging treatment options. 
 
It has often been considered that intrafraction motion is inconsequential compared 
with interfraction displacement.(92)  The use of electromagnetic transponders, such 
as Calypso, for real-time monitoring is cost prohibitive for many centres.  Recent 
innovations use the widely-available MV(218) or kV(219) imaging equipment to 
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automatically track intraprostatic FMs in real-time.  These new approaches account 
for intrafraction prostate motion by either termination of treatment if the FMs shift 
outside a set threshold, or tracking of the intrafraction motion with real-time 
adjustments of the dynamic MLCs.  The utilisation of the imaging equipment already 
integrated in linacs is set to make correction of intrafraction motion within reach of 
many centres. 
 
As correction of interfraction motion has become routine, more focus has been 
directed at the uncertainty related to intrafraction.  The interest in intrafraction 
motion has been highlighted by the emerging trend towards hypofractionation of 
prostate EBRT and boosting dominant intraprostatic lesions.  Real-time monitoring, 
and the ability to apply corrections, is emerging as an important tool in continuing to 
improve prostate EBRT precision and toxicity reduction.(218)  One of the greatest 
barriers to monitoring intrafraction motion has been the expense of equipment such 
as electromagnetic transponders.  The recent development of methods which utilise 
the existing infrastructure of the linac (MV or kV imaging with traditional FMs) 
promises to facilitate wider adoption of real-time tracking.(218-220).  Kilovoltage 
intrafraction monitoring (KIM) is an emerging solution for tracking the prostate in 
real-time.  KIM utilises planar projection images obtained by the kV imaging system 
as the gantry rotates about the patient.  Automatic segmentation of FMs and three-
dimensional reconstruction of the projections permits the KIM system to determine 
the trajectory of the prostate and potentially modify the beam to track motion with 
high accuracy. 
 
The use of hydrogel spacers, such as SpaceOAR® (Augmenix Inc., Waltham, MA) 
is gaining favour amongst clinicians as a means of reducing treatment-related rectal 
toxicity.(221)  The hydrogel is injected into the Denonvillier’s fascia in order to shift 
the prostate away from the rectum.(222)  The dose to the rectal wall is substantially 
decreased by this mechanical separation of the rectum from the high-dose target 
volume.(223, 224)  It is difficult to differentiate the prostate/hydrogel interface on 
CT.  Magnetic resonance imaging (MRI) is therefore recommended to delineate the 
prostate in the presence of hydrogels.(224)  The similarity of the prostate and 
hydrogel on CT also means FMs are indicated for precise treatment localisation.  The 
FMs are inserted by transperineal approach at the time of hydrogel insertion. 
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Another significant future path for prostate IGRT is MRI-guidance.  The promise of 
the MRI integrated linac is significant in terms of facilitating prostate IGRT.  It is 
likely that the superb soft-tissue image quality from MRI will facilitate prostate 
image-guidance without the use of surrogates.   
5.3. Future research directions 
To continue the assessment of soft-tissue alignment, the next stage of this assessment 
will be to determine the interobserver variability of CBCT localisation using images 
obtained without FMs in-situ.  This will allow the observers to utilise the reference 
CT when performing registration.  It will also be possible to include more observers 
and more patients in the analysis since the technique described by Jones et al. 
permits multiple observers in a single comparison.  This assessment, though, will not 
be able assess whether the use of the reference CT correlates with improved 
agreement with FM position since no markers will be used. 
 
Another worthwhile investigation would be to repeat the soft-tissue alignment with 
the same three observers to determine whether improvements have been achieved 
with further experience.  If large intra/interobserver variability and differences with 
the FMs was still found in the repeat measurements, it would add to the evidence 
that the image quality of CBCT is insufficient to permit soft-tissue guidance without 
additional PTV margins. 
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Chapter 6: Conclusion 
6.1. Recommendations 
The use of FMs is an effective means of correcting prostate organ motion prior to 
prostate EBRT.  Planar kV imaging has a significantly lower imaging dose with 
respect to either MV planar or volumetric kV options.  As this investigation has 
demonstrated, kV planar imaging with FMs benefits from excellent interobserver 
agreement.  RTs are able to consistently match FMs in either the online or offline 
environment.  Planar imaging with FMs is a quick, efficient means of IGRT.  There 
is considerably less time required to acquire and assess planar images compared with 
volumetric methods.  Minimising the time between imaging and treatment delivery 
is recommended in order to reduce the risk of intrafraction motion.  Such advantages 
should be considered when assessing the cost-effectiveness of FMs.  While not 
currently supported by PBS funding, the costs associated with FMs can be 
considered minimal with respect to the savings in efficiency, consistency, and 
overall benefit to the patient. 
 
While the use of FMs is highly recommended, it is recognised that not all patients 
are able to undergo the invasive implantation procedure required. In the absence of 
FMs, there is little role for planar imaging since motion of the prostate cannot be 
assessed.  If unable to utilise FMs, it is recommended to use soft-tissue localisation 
with kV CBCT.  The reference CT should be used to refine the localisation 
performance in conjunction with the reference contours (e.g. prostate, seminal 
vesicles, bladder, and rectum).  Anatomical features, such as intraprostatic 
calcifications can be used as surrogates to assist localisation.  It is also important to 
ensure measures are taken to optimise CBCT image quality while minimising 
imaging dose.  For instance, the scan length should be reduced where possible to 
minimise dose distal to the target.  This is likely to also improve image quality by 
reducing scatter received by the detector. 
 
Ultimately, it is important to remember that FMs and CBCT are not mutually 
exclusive.  The most prudent use of CBCT for prostate IGRT may include the use of 
FMs to reduce interobserver variability and improve localisation accuracy.  The 
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benefits of CBCT, such as visualisation of the soft-tissue prostate, seminal vesicles, 
rectum and bladder can then be utilised without sacrificing accuracy.  CBCT will 
still have an important role to play in the IGRT of patients with FMs, such as 
confirming compliance of bladder filling, monitoring rectal diameter and facilitating 
adaptive replanning. 
6.2. Conclusions 
Soft-tissue prostate localisation with CBCT can result in large differences from the 
isocentre position predicted by intraprostatic FMs.  There is considerable 
interobserver variability for soft-tissue guidance, which can be reduced by the use of 
FMs.  The goal of prostate radiation therapy to maximise tumour dose and minimise 
toxicity is helped by use of FMs to improve treatment accuracy and consistency. 
 
This investigation has added to the evidence supporting the importance of FMs in 
prostate IGRT.  FMs have been shown to reduce the interobserver variability of 
prostate localisation compared with soft-tissue localisation.  The unambiguous nature 
of FMs allows RTs to perform IGRT with great consistency when using planar kV 
imaging or CBCT. 
 
The increased interobserver variability found for alignment to soft-tissue should be 
considered in PTV margin design.   
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Figure A4.1: Bland-Altman plots for interfraction prostate motion (fiducial markers 
relative to bones) (a) superior-inferior; (b) left-right; and (c) anterior-posterior planes 
 
 
 
 
 
Table A4.1: Interfraction prostate motion with respect to bony anatomy.  (All 
measurements in mm) 
Direction Mean differences SD of differences 95 % LoA 
SI 0.2 3.15 -6.0 to 6.4 
LR 0.2 1.21 -2.2 to 2.5 
AP -0.5 2.45 -5.3 to 4.3 
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Figure A5.1:  Patient 1 DRRs 
 
 
Figure A5.2:  Patient 2 DRRs 
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Figure A5.3:  Patient 3 DRRs 
 
 
Figure A5.4:  Patient 4 DRRs 
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Figure A5.5:  Patient 5 DRRs 
 
 
Figure A5.6:  Patient 6 DRRs 
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Figure 6.1: Patient 7 reference CT 
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Figure 6.2: Patient 8 reference CT 
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Figure 6.3: Patient 9 reference CT 
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Figure 6.4: Patient 10 reference CT 
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Figure 6.5: Patient 11 reference CT 
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Figure 6.6: Patient 12 reference CT 
 
 
 
